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9Summary
Variation in the mutation rate along the human genome, if not properly understood and accounted 
for, has the potential to confound evolutionary studies, produce spurious driver candidates in cancer
studies, and hinder the diagnostics aimed at understanding the etiologies of genetic diseases. 
In this thesis I consider mutation rate variation in both the germ-line and somatic tissues, at varying 
scales. In the germ-line, the major advance of this thesis over previous works is use of direct 
methods to analyse the magnitude, scale and determinants of mutation rate variation. This has 
enabled us to tease apart the evolutionary and mutational forces, whilst directly quantifying the 
variation in the human mutation rate at different scales; at large scales the variation appears to be 
quite modest, however at the single nucleotide scale there is potentially huge cryptic variation in the
mutation rate. I envisage that within the near future, the increase in de novo mutations coming from 
pedigree studies will allow for even greater understanding.
I extend this work into somatic tissues, however due to the quality of data and heterogeneity of 
samples and cell types, the primary findings lean towards highlighting areas of improvement for 
next genereation sequencing (NGS) pipelines - I show ~4% of all single nucleotide variants from 
cancers appear to be errors - and develop methods with which future studies could provide more 
insight. With these methods and the ever increasing flow of somatic single nucleotide variants, 
coupled with the continual improvements in NGS technology, it should soon be possible to provide 
accurate answers to the questions posed of somatic mutation rate variation in this thesis.
10
1. Introduction.
1.1 General introduction
Mutation is an important phenomenon in biology, without it genetic variation can not arise in a 
population and evolution can not proceed. Mutation is also the source of genetic disease. In Homo 
sapiens (humans) deleterious germ-line mutations cause monogenic diseases and influence 
susceptibility to polygenic diseases such as autism and schizophrenia (Awadalla et al. 2010; Conrad
et al. 2011; Iossifov et al. 2012; Iossifov et al. 2014; Neale et al. 2012; O’Roak et al. 2012; O’Roak
et al. 2011; Sanders et al. 2012; Veltman & Brunner 2012). It follows that the rate at which 
mutations occur in an individual, and any variation in that rate, will impact both the evolution of 
that individual's species and the prevalence of disease in both the individual and their species at a 
population level. In somatic tissues deleterious mutations are responsible for diseases such as cancer
along with potentially contributing to a myriad of neurological disorders (Poduri et al. 2012; Poduri
et al. 2013; Rivière et al. 2012; Lee et al. 2012) and thus understanding the rate and spectrum of 
somatic mutation also has clinical importance. 
The focus is upon point mutations, which are the most abundant form of mutations in both the the 
germ-line and soma. Nucleotides are classified by their structure as either pyrimidines; cytosine (C) 
and thymine (T) or purines; adenine (A) and guanine (G). Mutations occurring between the same 
type are known as transitions, e,g C<>T or G<>A, all other point mutations are called transversions.
Transitions occur at a higher rate than transversions (Bulmer 1986; Cooper & Krawczak 1990; 
Gojobori et al. 1982; Hwang & Green 2004; Nachman & Crowell 2000).
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This introduction reviews the current understanding of human mutation rate variation, first of all in 
the germ-line, then in somatic tissues. This variation will be explored at different scales as it is 
evident that different processes are operative at different resolutions. The smallest scale at which 
variation can be studied involves at the single nucleotide level where the influence from 
neighboring nucleotides is very strong  (Bulmer 1986; Cooper & Krawczak 1990; Gojobori et al. 
1982; Hwang & Green 2004; Nachman & Crowell 2000). The next scale I consider is small scale 
regional variation - between 2-2000 nucleotides - which appears to be be largely influenced by local
GC content (Tomso & Bell 2003; Cohen et al. 2011) and chromatin dynamics (Ying et al. 2010). 
Above these scales we start to examine multiple kilo-bases (kb) and mega-bases (Mb); these are the 
scales that we associate with the molecular unit of heredity, the genes. At these large scales 
mutation rate appears to be related to a number of different features which will be discussed in 
section 1.3. Finally, I briefly explore variation at the largest scale, between chromosomes. As these 
form physically separate entities during cell division and can be differentially inherited, it is an 
obvious unit of scale to explore with very different reasons for exhibiting variation than the smaller 
scales.  This introduction will also attempt to highlight the commonalities and differences between 
patterns of somatic and germ-line mutation, with an additional focus upon the disconnect between 
the inferred patterns of substitutions from comparative genomics and direct findings from de novo 
mutations (DNMs) from recent trio studies. I close by exploring the importance of considering scale
in drawing conclusions on mutational processes.
1.2 The evolution of methods.
In 1947, through studying he emergence of the haemophilia phenotype, excessive bleeding, in a 
population, Haldane first measured the rates of male and female mutation at the X-linked 
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Haemophilia locus (Haldane 1947). This method relied upon assumptions of full penetrance and a 
consistent expressivity of one mutant disease causing locus.  These assumptions could not be 
confirmed at the time and still to this day can hinder efforts that use phenotypic incidence to predict 
genotype. This is exemplified by the fact that we now know Haemophilia can be caused by 
mutations at multiple X-lined and autosomal loci, and can exhibit variable expressivity depending 
upon the concentration of the different coagulation factors produced by these loci (Mannuci & 
Tuddenheim, 2001). Since Haldanes work, technological advances have continually transformed the
methods by which human germ-line mutation rates can be ascertained. However one thing that has 
remained relatively constant is the predominant reliance upon comparative studies from which 
mutation rates have been indirectly inferred. The initial comparison of cytochrome c (Margoliash 
1963) and Haemoglobin (Zuckerkandl & Pauling 1965) protein sequences from different species, 
gave way to comparisons of small DNA sequences, such as pseduogenes (Nachman & Crowell 
2000; Subramanian & Kumar 2003; Aguilar et al. 2005), and with the further development of 
shotgun sequencing, were followed by comparisons of whole genome sequences (Varki & Altheide 
2005). The great power afforded us from comparative genomics is however, not without its issues. 
The substitution patterns upon which these inferences are based, are the result of millions of years 
of accumulated DNMs, selection, drift and other potential mechanisms, such as recombination and 
the associated bias gene conversion (BGC), a process whereby mismatches formed during 
recombination are repaired in favour of G or C over A or T bases (Duret & Arndt 2008). All of these
can be hard to disentangle from each other. In addition the methods often require various 
assumptions about the neutrality of sequences or constancy of a molecular clock and generation 
times. Thus it is unclear exactly how well patterns of mutation derived from these indirect methods 
reflect the true pattern of germ-line DNMs. A more desirable method to study the patterns of germ-
line mutations involves direct measurements taken from pedigrees, but until recently these studies 
were restricted to small regions, commonly the mitochondrial control region (Sigurgardottir et al. 
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2000) and as such were limited in power. However, with the relatively recent emergence of next 
generation sequencing (NGS) as an affordable technology, the scope of pedigree studies has 
broadened to allow direct measurements of DNMs from hundreds of parent-offspring trios/quartets 
(Awadalla et al. 2010; Conrad et al. 2011; O’Roak et al. 2011; O’Roak et al. 2012; Iossifov et al. 
2012; Iossifov et al. 2014; Neale et al. 2012; Sanders et al. 2012; Veltman & Brunner 2012; Kong 
et al. 2012; Wong et al. 2016; Michaelson et al. 2012). This same technology has also facilitated an 
explosion in the sequencing of thousands of cancer genomes, resulting in more somatic mutations 
listed in public repositories - >40 million in the International Cancer Genome Consortium (ICGC) 
portal (https://icgc.org/) at the time of writing - than there are substitutions between the Homo 
sapeins and Pan troglodytes reference genomes. Prior to this, information about the somatic 
mutation rate was only available from calculations on single loci in cell lines (Araten et al. 2005; 
Herrero-Jimenez et al. 2000; Glaab & Tindall 1997; Lichtenauer-Kaligis et al. 1996; Bhattacharyya 
et al. 1995) or monogenic somatic disease prevalence (Hethcote & Knudson 1978; Fitzgerald et al. 
1983; Shoichi Mizunol, Shaw Watanabe, Takeo Iwama 1993; Iwama 2001; Luebeck & Moolgavkar 
2003; Hornsby et al. 2008).
1.3 Germ-line.
1.3.1 Between Genomes.
In the germ-line it has been shown that the mutation rates vary between species, for example Mus 
musculus have a rate of mutation twice that of Homo sapiens (Uchimura et al. 2015). Rates also 
vary between populations within a species, such as the surprising discovery that 5’-TCC-3’ → 5’-
TTC-3’ mutations occur more frequently in European Homo sapiens than African populations 
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(Harris 2015). Mutation rates also differ between the sexes (Conrad et al. 2011), with the majority 
of point mutations arising from the male germ-line (Hurst & Ellegren 1998; Haldane 1947), an 
asymmetry that increases with paternal age (Neale et al. 2012; O’Roak et al. 2012; O’Roak et al. 
2011; Iossifov et al. 2014; Iossifov et al. 2012; Michaelson et al. 2012; Kong et al. 2012; Francioli 
et al. 2015; Wong et al. 2016), and to a much lesser extent, maternal age (Wong et al. 2016). 
However, of primary interest here is that the mutation rate varies at different sites within a genome.
1.3.2 Comparative studies across the genome.
1.3.2.1 Whole chromosomes.
Variation occurs at different scales; At the level of whole chromosomes the greatest variation is seen
between the sex chromosomes and the autosomes (Lercher et al. 2001). The Y chromosome mutates
1.5-2 fold faster than the autosomes (Makova & Li 2002) which in turn mutate about 1.3 fold faster 
than the X chromosome (McVean & Hurst 1997). This is thought to be due to the aforementioned 
male mutation bias and because the Y chromosome, autosomes and X chromosome respectively 
spend, on average, less time in the male germ-line (Lercher et al. 2001). 
1.3.2.2 Large scale variatiom.
Comparative studies between species have ascertained that the mutation rate also varies at sub-
chromosomal, but still at large scales. For example between genes (Wolfe et al. 1989; Matassi et al. 
1999) or between Mb or multiple kb windows (Williams & Hurst 2000; Martin J. Lercher & Hurst 
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2002; Smith & Lercher 2002; M J Lercher & Hurst 2002; Hellmann et al. 2003; Tyekucheva et al. 
2008; Duret & Arndt 2008; Stamatoyannopoulos et al. 2009; Don et al. 2013; Prendergast et al. 
2007; Hodgkinson & Eyre-Walker 2011). This variation correlates with changes in GC content 
(Hellmann et al. 2005; Wolfe et al. 1989; Tyekucheva et al. 2008; Don et al. 2013; Chen et al. 
2010), recombination rate (Hellmann et al. 2003; Hellmann et al. 2005; Martin J. Lercher & Hurst 
2002; Tyekucheva et al. 2008; Duret & Arndt 2008; Don et al. 2013), replication time (Chen et al. 
2010; Pink & Hurst 2010; Stamatoyannopoulos et al. 2009; Don et al. 2013), distance to telomeres
(Hellmann et al. 2005; Tyekucheva et al. 2008; Chen et al. 2010; Don et al. 2013), chromatin state 
(Prendergast et al. 2007; Don et al. 2013) and nuclear lamina binding sites (Don et al., 2013; 
Ananda, Chiaromonte & Makova, 2011). However the magnitude of this large scale variation is 
low, only differing about 2-fold between the highest and lowest mutating windows (Chimpanzee 
Sequencing Consortium, 2005), All features combined only explain about 50% of the overall 
variance, with each factor only explaining a small proportion (Chen et al. 2010; Hodgkinson & 
Eyre-Walker 2011; Tyekucheva et al. 2008). The use of Mb windows has become something of a 
standard for genomic analyses. It has been argued that in the germ-line this is the most pertinent 
scale to study variation (Gaffney & Keightley 2005), 2005) and that it may be functionally 
associated with chromsome arhictecture (Yaffe et al. 2010; Don et al. 2013). However this validity 
of this assertion is by no means definitive, as will be explored in chapter 5.
1.3.2.3 Small scale regional variation
Between 2 and maybe 2,000 bases, different features associate with mutation rates. Here we start to 
see the effects of CpG islands, these are ~1kb regions with increased density CpG dinucleotides (C 
immediately 5' of a G) and overall increased GC content relative to the genomic average (Gardiner-
16
Garden & Frommer 1987). C followed by G is often methylated in mammals, and methylated 
cytosine undergoes a high rate of deamination to generate T resulting in a C>T mutation (Bulmer 
1986; Cooper & Krawczak 1990; Gojobori et al. 1982; Hwang & Green 2004; Nachman & Crowell
2000). This is the most hypermutable point mutation in the human genome (Hwang & Green 2004; 
Nachman & Crowell 2000), however as CpG dinucleotides are usually hypomethylated in CpG 
islands, so the rate of CpG>TpG decreases whilst the rate of other point mutation remains 
unaffected (Tomso & Bell 2003; Cohen et al. 2011). There is however a potential role for selection 
maintaining low-level CpG methylation in CpG islands (Panchin et al. 2016).
DNase hypersensitivity, intimately linked to nucleosome movement which controls chromatin 
dynamics (Hughes & Rando 2014; Gross & Garrard 1988), is another feature that appears to have 
an effect on the mutation rate, reducing the rate of ~200bp regions, particularly strongly for CpG > 
TpG transitions (Ying et al. 2010). Transcription factors bind at DNase hypersensitive sites to 
initiate a process that itself has mutational biases; Where the non-transcribed strand, likely due to 
the actions of more efficient transcription coupled repair on the transcribed strand, has an excess of 
C>T transitions (Mugal et al. 2009; Polak & Arndt 2008; Beletskii & Bhagwat 1996; Green et al. 
2003). However this small bias in the spectrum of mutation has very little effect on the overall 
mutation rate of transcribed sequences (Polak & Arndt 2008; Green et al. 2003; Hodgkinson & 
Eyre-Walker 2011) .
Multi-nucleotide mutations (MNMs) are complex mechanisms that produce two or more closely 
spaced mutations and the genomic distance over which these mechanisms act generally range from 
2 to 100 bases (Schrider et al. 2013; Schrider, Hourmozdi & Hahn, 2011; Averof et al. 2000; Smith 
et al. 2003; Harris & Nielsen 2014; Terekhanova et al. 2013; Rosenfeld et al. 2010). It is estimated 
that 1-2% of all human single nucleotide polymorphism (SNPs) (Rosenfeld et al. 2010; Schrider, 
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Hourmozdi & Hahn, 2011; Harris & Nielsen 2014) and up to 3% of substitutions between primates 
(Schrider, Hourmozdi & Hahn, 2011; Terekhanova et al. 2013) are caused by MNMs, ~50% of 
which are at adjacent nucleotides (Smith et al. 2003; Harris & Nielsen 2014; Seplyarskiy et al. 
2014; Chen et al. 2014). It is obvious that not accounting for these effects would inflate the 
apparent heterogeneity in mutation rates across the genome. This is difficult however as very little 
is known about the causes or how to suitably control for these effects. Although evolutionary 
processes could be responsible for MNMs, the evidence seems to favour a mutational origin for 
most MNMs (Schrider, Hourmozdi & Hahn, 2011; Averof et al. 2000; Smith et al. 2003; Harris & 
Nielsen 2014; Terekhanova et al. 2013). However the only MNM so far with robust evidence for a 
causative mechanism is GC>TT/AA. This mutation is a major signature of the error prone DNA 
polymerase zeta (Stone, Lujan & Kunkel, 2012; Harris & Nielsen, 2014; Seplyarskiy, Bazykin & 
Soldatov, 2014) accounting for 27% of all MNMs and thus responsible for a significant number of 
SNPs segregating in the human population (Harris & Nielsen 2014). Other emerging research from 
Homo sapien-Pan troglodytes alignments also attributes a significant proportion of MNMs 
separated by longer genomic distances to short template switching events (Löytynoja & Goldman 
2016). 
A further type of clustered mutation is result of overactive AID/APOBEC family of cytidine 
deaminses. These cause multiple clustered mutations spanning ~ 50bps with a preference for C>T/G
(Pinto et al. 2016; Seplyarskiy et al. 2016). Although this mechanism was first discovered in 
somatic tissues (Nik-Zainal et al. 2012; Alexandrov et al. 2013) where it potentially affects much 
larger regions, it has recently been shown to have played an important role in evolutionary 
dynamics, at least among the hominids (Pinto et al. 2016), displaying a preference for the lagging 
strand during DNA replication and potentially accounting for 20% of C>T/G human SNPs 
(Seplyarskiy et al. 2016). To what degree this could confound results based upon the independence 
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of point mutations is currently unclear, but is emerging as something that needs to be considered 
when analysing substitution and SNP data.
1.3.2.4 Single nucleotide scale
The greatest variation in the mutation rate is found at the single nucleotide level (Hodgkinson & 
Eyre-Walker 2011). In part this variation is due to context - the identity of the nucleotides 
surrounding a site (Bulmer 1986; Cooper & Krawczak 1990; Gojobori et al. 1982; Hwang & Green 
2004; Nachman & Crowell 2000). The most well known example of a context effect is the 
previously mentioned CpG deamination where methylated C undergoes a high rate of deamination 
to generate T (Bulmer 1986; Cooper & Krawczak 1990; Gojobori et al. 1982; Hwang & Green 
2004; Nachman & Crowell 2000). It has been estimated that CpGs undergo rates of mutation 10-15 
fold higher than other sites in the human genome (Hwang & Green 2004; Nachman & Crowell 
2000) and generate ~20% of all mutations (Fryxell & Moon 2005). There are also other context 
effects, but these lead to variation in the mutation rate of only 2 to 3-fold (Hwang & Green, 2004; 
see Fig. 1a in (Hodgkinson & Eyre-Walker, 2011)), and the mechanism of this variation is poorly 
understood. 
There also appears to be variation in the mutation rate at the single nucleotide level that does not 
depend upon simple context, variation that has been termed "cryptic variation in the mutation rate". 
This variation is cryptic in the sense that it can be detected within currently available mutation and 
substitution data and we can quantify the magnitude of it, but we currently have no explanation for 
its cause (Hodgkinson & Eyre-Walker 2011). The evidence for this variation comes from 
comparisons of various primates, including Homo sapiens, that there are an excess of sites in which 
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different species share a SNP, even when the influence of context on the mutation rate is taken into 
account. These excess SNPs could be due to sequencing error, assembly error of paralogous 
duplications or ancestral polymorphism. However, the evidence is in favour of a mutational 
mechanism that is not associated with simple context (Hodgkinson et al. 2009; Johnson & 
Hellmann 2011). It has been estimated that cryptic variation may generate more variance in the 
mutation rate than simple contexts, such as the CpG effect (Hodgkinson et al. 2009; Johnson & 
Hellmann 2011). 
1.3.3 Direct Methods.
More direct approaches, using DNMs from trio data (Hodgkinson et al. 2009), enable the 
elucidation of germ-line mutational patterns without the noise of evolutionary processes, such as 
selection. Although rapidly increasing, the number of currently available whole genome DNMs for 
analysis are small (~43,000) when compared to the number of substitutions between Homo sapiens 
and Pan troglodytes whole genomes, and the size of the Homo sapiens genome. However, one thing
that is starting to emerge, is that DNM rate variation, at least at large scales, may be less than 
previously suggested by patterns of substitutions from comparative studies (Michaelson et al. 2012;
Kong et al. 2012; Wong et al. 2016; Francioli et al. 2014). In one of the first trio studies to compare 
whole genomes of Homo sapiens, Michaelson et al. (Michaelson et al. 2012) only find significant 
effects on site mutability for GC content at the 1Mb scale, recombination rate at the 100kb scale, 
nucleosome occupancy and DNase hyper-sensitivity at the 100bp scale and simple nucleotide 
context at the 1bp scale (Michaelson et al. 2012), and out of these simple nucleotide context has by 
far the strongest association. All other associations from this study appear insignificant, however 
their influence can not be fully disregarded; this study could be considered to be under-powered, 
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with only 581 DNMs from which to draw conclusions. In chapter 5 we seek to investigate these 
relationships further with the greater power enabled by the ~75 fold increase in the number 
available DNMs.
Probably the most noticeable difference between patterns of DNMs and substitutions concerns 
replication time. This shows a strong relationship with increased substitutions and SNPs in later 
replicating regions (Michaelson et al. 2012), but with respect to DNM density appears to be either 
insignificant (Stamatoyannopoulos et al. 2009; Chen et al. 2010) or has a small, converse 
relationship with paternal age; The number DNMs not only increase with paternal age (O’Roak et 
al. 2012; O’Roak et al. 2011; Iossifov et al. 2012; Iossifov et al. 2014; Kong et al. 2012; Neale et 
al. 2012; Michaelson et al. 2012), but are also overrepresented in early replicating regions 
(Francioli et al. 2015).
The most Robust evidence of mutation rate variation from direct studies is the quantification of the 
relative rates of mutations for four major classifications of DNMs; According to Kong et al. (Kong 
et al. 2012), the hyper-mutable CpG transitions (CTs) driven by spontaneous deamination (Bird 
1980) occur 30 fold more often than the least mutable group, non-CpG transversions (NTv), with 
CpG transversions (CTv) and non-CpG transitions (NTs) occurring 2-3 fold more frequently than 
NTv. Interestingly, the data from Michaelson et al. (Michaelson et al. 2012) only estimates the rate 
for CTs to be ~20 fold greater than NTv, highlighting possible procedural differences associated 
with NGS technologies and pipelines or maybe reflecting ascertainment biases (Eyre-Walker & 
Eyre-Walker 2014). Similar values were also inferred over a decade earlier from comparisons of 
pseudogenes (Nachman & Crowell 2000), suggesting that inferences from established comparative 
methods represent the overall spectrum of DNMs relatively well, despite the apparent lack of 
agreement regarding associations with genomic features like replication time.
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Direct methods have confirmed that idea of a mutational origin for MNMs using human trio data, 
estimating between 2.1% to 6.9% of all DNMs are MNMs, the lower bounds of which better agree 
with the estimates from comparative methods (Schrider, Hourmozdi & Hahn, 2011). Direct 
methods, in the form of mutation accumulation experiments, have also extended the search for 
MNMs to other organisms. These have produced similar estimates of between 2.8% and 3.4% for 
species as diverse as Chlamydomonas reinhardtii (Ness et al. 2015), Drosophila melanogaster, 
Caenorhabditis elegans, Arabidopsis thaliana and Saccharomyces cerevisiae (Schrider, Hourmozdi 
& Hahn, 2011; Schrider et al., 2013). It is starting to become clear that MNMs are ubiquitous across
taxa, and through violating the assumption of mutational independence, have the potential to not 
only confound studies of mutation rate heterogeneity, but also to enable unique evolutionary 
mechanisms. For example, the GC>TT MNM described previously makes it possible for one 
mutational event to convert the codon GCU (alanine) to UUU (phenylalanine), a change of amino 
acids that is not possible with just one point mutation.
It is clear that the much of information we have about mutation rate variation has been inferred 
from comparative studies. It is possible that the importance of this variation to DNM rates has been 
over-interpreted. This may be particularly pertinent at larger scales. To address this further, analysis 
of mutation rates using direct methods is required, and this is where chapters 2 and 5 of this thesis 
aims to contribute. Chapter 2 provides the first quantitative analysis of cryptic variation using direct
methods, whilst chapter 5 examines, the relationship between DNMs, substitutions, SNPs and 
genomic features at different scales.
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1.4 Somatic.
1.4.1 The overall rate of somatic mutation.
Prior to NGS technology, Information about the somatic rate of mutation was only known from 
calculations from cell line studies at single loci, like the HPRT (Bhattacharyya et al., 1995; 
Lichtenauer-Kaligis et al., 1996; Glaab & Tindall, 1997; Herrero-Jimenez et al., 2000) and PIG-A 
genes (Araten et al., 2005), or from monogenic somatic disease prevalence such as unilateral 
retinoblastoma caused by mutations in RB1 (Hethcote & Knudson, 1978; Fitzgerald, Stewart & 
Suckling, 1983) and colon cancer caused by mutations in APC (Mizunol, Watanabe & Iwama, 1993;
Iwama, 2001; Luebeck & Moolgavkar, 2003; Hornsby, Page & Tomlinson, 2008). These studies 
calculated the somatic mutation rate to be 10-1000 fold higher than the germ line (Lynch, 
2010) with the higher frequencies largely dependent on mismatch repair (MMR) deficiency 
(Mizunol, Watanabe & Iwama, 1993; Glaab & Tindall, 1997; Iwama, 2001; Luebeck & 
Moolgavkar, 2003; Hornsby, Page & Tomlinson, 2008). Some studies in HPRT (Lichtenauer-
Kaligis et al., 1996) did uncover variation in the mutation rate dependent upon genomic location, 
however no reason could be given for this.
With the application of NGS to whole cancer genomes, huge numbers of somatic single nucleotide 
variants (SNVs) quickly became available for analysis. It soon became clear that the mutation rate 
varied massively both within and between cancer types (Lawrence et al., 2013) and that the overall 
mutation rate of a cancer explained 50% of the lifetime risk of developing cancer (Hao, Wang & Di,
2016). Further to this, different cancers displayed different mutational "signatures", thought to be 
indicative of the underlying genomic instability (Nik-Zainal et al., 2012, 2016; Alexandrov et al., 
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2013; Morganella et al., 2016). However, it could be argued that adequate controls of non-
cancerous whole somatic genomes are missing. Somatic SNVs are generally identified as such if 
they are present at sufficient frequency in DNA from tumour samples, but absent in the peripheral 
blood lymphocytes (a proxy for the germ-line) of the same individual. But despite thousands of 
whole cancer genomes being made freely available through portals such as ICGC (Zhang et al., 
2011), very few non-cancerous somatic cells have been sequenced. It is known that there is much 
diversity in large scale genomic aberrations of healthy somatic cells; copy number variations (CNV)
and chromosomal ploidy changes have been reported (Yurov, 2005; O’Huallachain et al., 2012). 
Healthy tissues exposed to ultra-violet light carry 2-6 DNMs per Mb, similar to cancerous tissues, 
20% of which harbour driver mutations (Martinocorena & Campbell, 2015). A further study in 
healthy somatic tissues from Mus musculus suggested a bias for C>T, C>A and G>T in different 
tissues, highlighting the potential diversity of the somatic mutational spectrum dependent upon cell 
type, age and exposure to mutagens (Behjati et al., 2014). Thus even though we now have millions 
of somatic SNVs obtained in a direct manner from whole genome sequenced cancers, it is not clear 
to what extent there is variation in non-diseased tissues and to what extent the patterns found in 
cancer genomes represent neutral variation or clonal selection during tumour development. 
1.4.2 Somatic mutation rate variation across the genome
1.4.2.1 Whole Chromosomes.
Contrary to the germ-line, chromosomes in somatic cells spend the entirety of the time in just one 
gender, with somatic tissues from both sexes experiencing roughly similar numbers of cell 
divisions. Thus the driving forces behind mutation rate variation in the autosomes and the X/Y 
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chromosomes should no longer be applicable. The little research that has been done on this subject 
suggests that the X chromosome has a density of mutations roughly similar to the autosomes 
(Hodgkinson, Chen & Eyre-Walker, 2012); the Y chromosome data was not available in this study.
1.4.2.2 Large scale.
Efforts to understand mutation rate heterogeneity in somatic SNVs, like germ-line studies, has been 
primarily carried out at the Mb scale (Hodgkinson, Chen & Eyre-Walker, 2012; Schuster-Bockler &
Lehner, 2012; Lawrence et al., 2013; Liu, De & Michor, 2013; Polak et al., 2015; Supek & Lehner, 
2015) or 100kb scale (Koren et al., 2012). These have revealed many similarities to germ-line 
determinants from comparative studies. One of the first study showed that at the megabase scale, 
replication time, distance to telomere, GC content, gene density and nucleosome occupancy 
explained about 40% of the variance in mutation density, but each factor only explains very little of 
this variance (Hodgkinson, Chen & Eyre-Walker, 2012). Subsequent studies using considerably 
more genomes and investigating many more genomic variables claim to have extended the 
explainable variance to between 55% (Schuster-Bockler & Lehner, 2012) and 86% (Makova & 
Hardison, 2015; Polak et al., 2015), attributing most of the variance to histone modifications - 
particularly H3K9me3 - responsible for chromatin organisation. Chromatin architecture in general 
has been cited as the major determinant of large scales somatic mutation rate variation, where 
regions of closed chromatin, associated with histone acetylation in the form of H3K27, harbour 
higher mutation rates with open chromatin appearing less mutable, possibly due to easier access to 
DNA repair pathways (Schuster-Bockler & Lehner, 2012; Makova & Hardison, 2015). The 
aforementioned mutational increase in late replicating regions is also associated with an increase in 
transversions over transitions and appears unequivocally stronger in somatic tissue (Woo & Li, 
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2012) than the germ-line, in which recombination rate appears to be the more dominant association 
(Duret & Arndt, 2008). Similar to the germ-line, the effect of transcription on mutation rate, 
although highly evident in somatic cells, appears to be weak (Koren et al., 2012; Hao, Wang & Di, 
2016). Another form of mutation pertinent to cancer etiology is that of fragile sites (FS) (Debatisse 
et al., 2012; Ozeri-Galai, Bester & Kerem, 2012). These are large regions of genomic instability that
are associated with late replication and overlap large tumour suppressor genes, resulting in double 
strand breaks that that potentially knock out the tumour suppressors (Wilson et al., 2015), however 
very little is known about the biological mechanism of induction or how this form of large scale 
genomic instability is associated with SNVs. Chapter 4 attempts to tackle this question by 
investigating the correlation of fragile sites with SNVs and replication time.
With the obvious goal of cancer genomics being to discover the causative drivers of tumorigenesis, 
it is apparent that not properly accounting for mutational heterogeneity will lead to spurious results. 
Thus methods have been developed to control for the background rate of mutation based upon these
associations. One such method is MutSigCV which primarily accounts for large scale variation in 
replication time and has proven successful in eliminating mutations in olfactory genes which would 
appear to have no biological relevance to cancer (Lawrence et al., 2013). However the level of 
variation seen at this scale only varies by about 5-fold (Hodgkinson, Chen & Eyre-Walker, 2012; 
Lawrence et al., 2013; Makova & Hardison, 2015). It is not currently clear how this compares to the
magnitude of variation at the 1Mb scale in the germ-line, but data from taking comparative methods
currently suggest a more modest 2-3 fold variation and so it is quite possible that there is a large 
disconnect between the two. Indeed the determinants of somatic variation only moderately agrees 
with data from comparative germ-line methods (Hodgkinson & Eyre-Walker, 2011; Makova & 
Hardison, 2015).  Further, this 5-fold variation is also a fraction of the level found in both the soma 
and the germ line at the single nucleotide scale and thus the relevance of these large scale 
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associations to the major driving forces of mutation rate heterogeneity is questionable - being able 
to explain 86% of a quantity that only varies 2-3 fold may not explain much. 
1.4.2.3 Small scale regional
There is much less data on small scale regional variation in the somatic mutation rate, and what 
there is seems to mimic the germ-line quite well. The over-expression of APOBEC enzymes was 
first discovered in somatic tissues (Nik-Zainal et al., 2012, 2016; Alexandrov et al., 2013) and is the
one mechanism where more is known about the soma than germ-line. It can cause clusters of 
TpC>TpT/TpG mutations, independently of replication time (Morganella et al., 2016), potentially 
spanning up to 200kb (Roberts et al., 2012). It has also been suggested that it can be triggered by 
human papilloma virus (HPV), although the mechanism of action has yet to be determined 
(Hollstein et al., 2016). In addition it has also been implicated in causing complex mutations by 
attacking single stranded DNA in palindromic sequences, causing the recurrent MNM TGAACAA 
> TAAATAA in the PLEKHS1 promoter region (Nik-Zainal et al., 2016). Interestingly though, 
unlike the many studies in the germ-line, there is yet to be any study conducted into the proportion 
of somatic DNMs that are MNMs. Nucleosome occupancy, like the germ-line also reduces mutation
rates, although it has been shown to be mutation signature specific, as are the somatic associations 
with replication time (Morganella et al., 2016).
1.4.2.4 Single nucleotide level
The high heterogeneity between cancers in exposure to both exogenous and endogenous mutagens, 
hypermutators and various form of DNA editing and repair result in huge differences in rates of 
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mutation (Nik-Zainal et al., 2016). For example smoking associated lung cancers will be smothered 
with C>A mutations, whereas melanomas will be enriched for the C>T or CC>TT  mutations 
resulting from UVb radiation (Hollstein et al., 2016). Oxidative DNA damage which also result in 
C>A mutations (Mugal, von Grunberg & Peifer, 2009), requires subsequent repair by the nucleotide
excision repair (NER) pathway (Melis, van Steeg & Luijten, 2013), which has its own mutational 
biases (Roberts & Gordenin, 2014). MMR deficient colon cancers will be enriched for both C>T  
and C>A mutations (Alexandrov et al., 2013) and so it is obvious not only how heterogeneous 
different cancers are but also how hard it is to distinguish the causes of this heterogeneity. Chapter 3
attempts the first single nucleotide scale quantification of cryptic variation in the somatic mutation 
rate, by controlling for nucleotide context, thus aiming to ascertain the non-random patterns of 
mutation. However, what transpired was a clear indication of the current limitations of NGS 
technology and thus a clear quantification is not currently possible. The best estimates of single 
nucleotide somatic mutation rates so far appears to suggest that just like in the germ-line, CpG 
deamination occurs in a relatively clock like manner (Alexandrov et al., 2015). However, where in 
the germ line CpG deamination would be expected to be clock like respective to absolute time it 
appears to fit better with the number of cell divisions in the soma (Alexandrov et al., 2015).
1.5 The question of Scale
As seen above, scale is important to consider as it can produce different results, 1Mb has been 
suggested as the correct scale at which to study mutation rate variation (Gaffney & Keightley, 
2005). At this scale the mutation rate varies maximum 3 fold in divergence data and 5 fold in 
somatic data across the genome (Hodgkinson & Eyre-Walker, 2011; Hodgkinson, Chen & Eyre-
Walker, 2012; Lawrence et al., 2013; Makova & Hardison, 2015). The only study of DNMs to look 
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at the variation at this scale does not provide much evidence for such strong variation (Michaelson 
et al., 2012). More recently it has been suggested that actually the single nucleotide level is most 
appropriate scale at which to consider mutation rates (Ness et al., 2015), where the variation is 
much greater, up to 30 fold due to simple nucleotide context (Kong et al., 2012; Michaelson et al., 
2012) and perhaps greater if considering the evidence for cryptic variation (Hodgkinson, 
Ladoukakis & Eyre-Walker, 2009; Johnson & Hellmann, 2011) . It is possible that the patterns of 
variation seen at the Mb scale are just manifestations of processes that occur at much smaller scales.
Chapter 5 investigates the relationship of divergence with DNMs and recombination rate and other 
genomic features at 1Mb, 100kb scales to try to further understand four particular points; (i) how 
does the variation in DNM rate differ between these two scales, (ii) how well does variation in 
divergence along the genome represent the variation in DNMs, (iii) How do these patterns change 
over evolutionary time, and (iv) how well do the often cited determinants of mutation rate represent 
the variation in DNM density along the genome.
1.6 The contribution of this thesis
1.6.1 Overview
In the germ-line, mutation rate variation has often been inferred from divergence data which can 
include other confounders, such as bias gene conversion and natural selection. Only recently has the
number of DNMs from pedigrees become substantial enough to be able to directly quantify 
mutation rate variation. In the soma, a proliferation of whole genome sequenced cancers have also 
provided millions of somatic SNVs to be analysed, showing both similarities and differences to 
patterns in the germ-line inferred from divergence. This thesis aims to further quantify mutation rate
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variation in the germ-line directly from DNMs, exploring the magnitude of this variation at multiple
scales and drawing comparisons to features that are associated with variation in rates of divergence. 
Additionally, it lays the ground for further exploration of these themes in somatic tissue, for which 
there is an increasing abundance of data, but sometimes lacking accuracy and suitable controls.
1.6.2 Chapter 2, cryptic variation in the germ-line.
In chapter 2, I start by providing further evidence for cryptic variation in the mutation rate, 
something that has only previously been inferred from indirect methods. Using the distribution of 
recurrent DNMs in autosomal dominant disease genes, I show that at the single nucleotide level, 
cryptic variation exists and may be huge, potentially dwarfing that of simple context mutations, 
such as CpG deamination. This is the first direct evidence of cryptic variation in the mutation rate in
the germ-line
1.6.3 Chapter 3, cryptic variation in cancers and sequencing error.
In chapter 3, I extend the methodology of chapter 2 to exploit the vast number of somatic SNVs 
produced from the application of NGS methods to whole cancer genomes. This is the first attempt 
to quantify cryptic variation at the single nucleotide level in somatic tissues. The large number of 
mutations, ~3 million, allowed an extension of the method to consider each triplet - the base at 
which the SNV occurs and the neighboring bases - individually. The level of heterogeneity present 
was huge with an excess of recurrently hit sites that, when modelled with an additional parameter, 
indicated a high level of sites specific error in NGS. With this level of error, quantifying the cryptic 
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variation was not possible, but this has laid the ground for future similar attempts when the error 
rate of sequencing technology improves and has the potential to produce a highly accurate picture 
of mutation rate heterogeneity at the single nucleotide level.
1.6.4 Chapter 4, fragile sites and somatic mutation rate variation.
In chapter 4, using the same SNV data as chapter 3, I investigate the relationship of fragile sites 
with SNVs and replication time. I show that there is currently no evidence for an association of 
fragile sites and SNVs, suggesting an independent biology for both forms of mutation. There is 
however huge potential for this approach to be improved in the near future. The rapid output of 
cancer data that we are currently witnessing means increased sample homogeneity and increased 
power to detect variation. 
1.6.5 Chapter 5, Divergence, de novo mutations and the scale of variation.
In this final chapter, I return to the germ-line. Most of our understanding about variation in the 
mutation rate has been inferred using indirect methods involving, alignments and SNPs. Using a 
combination of alignments and the ~43,000 DNMs now available from pedigrees, I show that the 
degree to which variation in substitutions from alignments represents human DNMs is quite weak 
for most substitution types. I provide evidence that this lack of correlation between divergence and 
DNM density along the genome is likely due to the actions of GC-biased gene conversion, and 
investigate the differing relationships of genomic features, like replication time and nucleosome 
occupancy, with divergence and DNM density. I also propose that recombination is both mutagenic 
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and has other evolutionary effects, shown by its independent relationships with both DNM density 
and divergence. Furthermore these patterns appear to be relatively well conserved throughout the 
primates. Finally I provide evidence suggesting that the magnitude of mutation rate variation at the 
large scale is actually very small and thus the pertinent scale at which to study mutation rate 
variation is likely to be at smaller scales.
1.6.6 Summary.
In Summary, this work utilises the recent proliferation of data flowing from NGS technologies to 
confirm, for the first time using direct methods, previous findings relating to the determinants, 
magnitude and scale of variation in the human mutation rate. These findings concern both germ-line
and somatic tissues, contributing not only to evolutionary biology, but also having a clinical 
relevance for both inherited diseases and cancer research. Thus there is potential widespread 
applicability of not only the findings, but also future implementations of the methods developed 
herein.
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2. Extensive Variation in the Mutation Rate Between and
Within Human Genes Associated with Mendelian Disease.
2.1 Abstract
We have investigated whether the mutation rate varies between genes and sites using de novo 
mutations (DNMs) from three genes associated with Mendelian diseases. We show that the relative 
frequency of mutations at CpG dinucleotides relative to non-CpG sites varies between genes and 
relative to the genomic average. In particular we show that the rate of transition mutation at CpG 
sites relative to the rate of non-CpG transversion is substantially higher in our disease genes than 
amongst DNMs in general; the rate of CpG transition can be several hundred-fold greater than the 
rate of non-CpG transversion. We also show that the mutation rate varies significantly between sites
of a particular mutational type, such as non-CpG transversion, within a gene. We estimate that for 
all categories of sites, except CpG transitions, there is at least a 30-fold difference in the mutation 
rate between the 10% of sites with the highest and lowest mutation rates. However, our best 
estimate is that the mutation rate varies by several hundred-fold variation. We suggest that the 
presence of hypermutable sites may be one reason certain genes are associated with disease.
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2.2 Introduction.
There is evidence that the mutation rate varies substantially across the human genome in the germ-
line from studies of de novo mutations (DNMs) (Francioli et al. 2015; Michaelson et al. 2012) and 
from comparative genomics (reviewed in (Hodgkinson & Eyre-Walker 2011)). Although this occurs
at a number of different scales the most dramatic variation is seen at the single nucleotide level 
(Hodgkinson & Eyre-Walker 2011). In part this variation is due to context - the identity of the 
nucleotides surrounding a site (Bulmer 1986; Cooper & Krawczak 1990; Gojobori et al. 1982; 
Hwang & Green 2004; Nachman & Crowell 2000). The most well-known example of a context 
effect is that of CpGs; C followed by G is often methylated in mammals, and methylated cytosine 
undergoes a high rate of deamination to generate T (Bulmer 1986; Cooper & Krawczak 1990; 
Coulondre et al. 1978; Gojobori et al. 1982; Hwang & Green 2004; Nachman & Crowell 2000). It 
has been estimated that CpGs undergo rates of mutation 10-15 fold higher than other sites in the 
human genome (Hwang & Green 2004; Nachman & Crowell 2000) and generate ~20% of all 
mutations (Fryxell & Moon 2005). There are also other context effects, but these lead to variation in
the mutation rate of only 2 to 3-fold (Hwang & Green 2004). 
In addition to variation associated with context, there also appears to be variation at the single 
nucleotide level that does not depend upon the identity of the adjacent nucleotides, at least not in a 
simple manner, variation that has been termed cryptic (Hodgkinson et al. 2009). The evidence for 
this variation initially came from the observation that there is at least a 50% excess of sites in which
humans and chimpanzees share a single nucleotide polymorphism (SNP), even when the influence 
of context on the mutation rate is taken into account (Hodgkinson et al. 2009). Such an excess could
be due to sequencing error, assembly error of paralogous duplications or ancestral polymorphism. 
However, several lines of evidence suggest that these explanations do not explain the excess of 
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coincident SNPs. First, the distribution of allele frequencies amongst coincident SNPs is identical to
non-coincident SNPs (Johnson & Hellmann 2011); if coincident SNPs were due to assembly errors 
or ancestral polymorphisms we would expect them to be more frequent in the population than other 
SNPs. Second, sequencing coverage is no greater at coincident SNPs than other sites (Johnson & 
Hellmann 2011). And third, there is also an excess of coincident SNPs between human and macaque
(Hodgkinson et al. 2009), two species which are very unlikely to share ancestral polymorphisms. 
There is also an excess of sites with substitutions in two independent pairs of primate species 
(Johnson & Hellmann 2011). These lines of evidence therefore suggest that the excess of coincident
SNPs most likely arises from variation in the mutation rate that is not associated with context, at 
least not sequence contexts that are close to the site in question. It has been estimated that cryptic 
variation may generate more variance in the mutation rate than simple contexts, such as the CpG 
effect (Hodgkinson et al. 2009). 
Although, variation in the mutation rate is most conspicuous at a single nucleotide scale it has also 
been known for some time that the mutation varies at larger scales in the human genome (Matassi et
al. 1999; Michaelson et al. 2012; Spencer et al. 2006). The scale of this variation remains poorly 
characterised but a recent analysis of where DNMs occur suggest that the variation is probably at a 
scale of 10,000s of base pairs (Michaelson et al. 2012). The variation in the rate of CpG and non-
CpG mutations appears to be at least partly independent, because the variation correlates to different
genomic variables (Tyekucheva et al. 2008), but no systematic analysis of the relative rates of CpG 
and non-CpG mutation has been performed to our knowledge.
Here we investigate two aspects of variation in the mutation rate. First, does the relative frequency 
of transition and transversion mutations at CpG and non-CpG sites differ between genes, and 
second, is there variation in the mutation rate for transition and transversion mutations within CpG 
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and non-CpG sites (e.g. does the rate of transition mutation differ between CpG sites within a single
gene). We address these questions using a dataset of de novo mutations (DNMs) that have been 
discovered during clinical screening in three genes associated with Mendelian diseases. In each case
the DNMs were discovered in an unbiased manner – the causative gene was sequenced in a patient 
with the disease and their parents who did not have the disease. 
2.3 Methods
2.3.1 Data
DNMs were discovered as part of routine clinical screening for individuals suffering from bilateral 
retinoblastoma, neurofibromatosis type I and Rett’s syndrome; these diseases are caused by 
mutations in RB1, NF1 and MECP2 respectively. All data were collected after Ethics committee 
approval at each of the institutions involved. 
The MECP2 data were gathered from RettBASE, International Rett Syndrome Foundation MECP2 
Variation Database (http://mecp2.chw.edu.au), a curated database for MECP2 variants from 
research and clinical laboratories (Christodoulou et al. 2003). Variants included in this study were 
limited to those for which parental testing had been carried out, with both parents tested for female 
patients, or maternal testing for male patients, since the gene is X-linked. Only variants from studies
in which exons 2-4 had been sequenced were included, and our analysis was restricted to this part of
the gene. 
The NF1 data were gathered from the NF1 LOVD database 
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(https://grenada.lumc.nl/LOVD2/mendelian_genes/home.php?select_db=NF1). Both parents were 
tested for the pathogenic mutation and the father was tested for paternity. We only included studies 
in which all exons had been sequenced in transcript variant 2, this differs from transcript variant 1 
in missing exon 31 (formerly known as exon 23a). 
The RB1 data came from three laboratories. Mutations were identified using a number of 
approaches including sequencing, single strand conformational polymorphism, heteroduplex 
analysis and high resolution melt analysis. Mutations were confirmed in each case by direct 
sequencing. There is alternative start codon in RB1 (Sanchez-Sanchez et al. 2007) so exon 1 was 
ignored in the analysis.  Both parents were tested for all RB1 variants. Some of the RB1 data has 
been previously published (Price et al. 2014). 
The transcript numbering that we use is from NM_004992.3 for MECP2, NM_000267 for NF1 and 
NM_000321.2 for RB1. We focus our analysis on nonsense mutations since nonsense mutations are 
more likely to have consistent phenotypic effects (see results section for further discussion).
2.3.2 Testing for mutation rate variation between genes
We performed two tests of mutational rate heterogeneity. First we tested whether the relative rates 
of CpG transitions, CpG transversions, non-CpG transitions and non-CpG transversions were 
significantly different between genes and between the genes and the background rate. To do this we 
performed a chisquare goodness-of-fit test, in which we calculated the expected number of CpG 
transitions and transversions, and non-CpG transitions and transversions, assuming that the ratios 
between the various mutational types were the same in the two genes, by finding the parameters of a
simple model which minmised the chi-square statistic. We assumed that each gene has its own 
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“mutation rate”, which reflects both the intrinsic mutation rate and the probability that the mutation 
comes to clinical attention; let this be μi. If we assume that the relative rates of the different 
mutation categories are the same in two genes then without loss of generality we can let the rate of 
non-CpG transversions rate be μi and the rates of CpG transition, CpG transversion and non-CpG 
transition be μi rcts, μi rctv, and μi rnts, where rcts, rctv and rnts are shared between the two genes. To test 
whether the patterns of mutation are the same we find the values of μi, rcts, rctv and rnts that minimise 
the chi-square value, comparing the observed and expected values. Having found the parameters 
that minimise the chi-square value we performed a goodness of fit test using the ch-square value 
with 3 degrees of freedom (because we have eight observations and we have estimated 5 
parameters).
2.3.3 Testing for mutation rate variation within genes
Second, we tested whether the rate of mutation varied within a mutational category (e.g. CpG 
transitions). If the rate of mutation is the same across all sites of a particular type then DNMs 
should be randomly distributed across those sites. To test whether DNMs tend to recur at sites more 
often than by chance we generated the expected number of sites hit recurrently by DNMs by 
randomly distributing the observed number of DNMs of the required type (e.g. CpG transitions) 
across the sites of that type that could generate a nonsense mutation. For each randomized dataset 
we tabulated the number of sites a site was hit zero, once, twice…etc by a DNM. By repeating this 
randomization 10,000 times we derived the expected distribution of DNMs (i.e. the number of times
a site is expected to have been hit by one, two…etc DNMs). We compared the observed to the 
expected using a chi-square test. However, the test statistic is unlikely to be chi-square distributed 
because some of the expected values can be very small, We therefore empirically determined the 
distribution of the chi-square statistic by calculating the chi-square statistic for each simulated 
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dataset using the expected values estimated across all simulated datasets (as we did for the observed
data). We then compared the observed chi-square statistic to this distribution. The p-value was the 
proportion of simulated datasets that had a chi-square value greater than observed chi-square value 
plus half the simulated datasets that had an identical chi-square value; this latter condition prevents 
the test being overly conservative when there are few DNMs. We performed simulations to check 
that this method did not generate excessive levels of type I error. For a given number of DNMs and 
sites we randomly allocated DNMs across sites and tabulated the number of sites that had been hit 
0,1,2…etc times. We then performed the analysis as though this was real data, and repeated this 
1000 times for a given combination of sites and DNMs. Simulations confirm that it does not 
increase the level of type I error, although it can decrease it when there are very few DNMs (i.e. the 
test can be overly conservative). 
To combine probabilities from the heterogeneity tests we used the unweighted z-method (Whitlock 
2005); in this method we find the value of a normal distribution deviate, with a mean of zero and 
variance of one, that would yield the corresponding p-value – the z-value. These z-values can be 
added to yield a z-value with an expected value of zero and a variance equal to the number of tests 
that have been combined. The overall p-value is then obtained by converting the combined z-value 
back into a p-value. We set p-values in which no simulated data had a greater chi-square value to 
0.0001, and no simulated data had a smaller chi-square to 0.9999.
2.3.4 Parameter estimation
"In modelling the variation in the mutation rate, various models have been used; early discrete rate-
class models provided good approximations (Fitch & Margoliash, 1967) but became 
computationally unfeasible when more than 3 rate-classes were included (Yang, 1994). However, a 
39
continuous model based on the gamma distribution, which is therefore not limited to just 3 rate-
classes, has been shown to provide a good fit to many datasets (Golding, 1983). The gamma 
distribution, modeled with a mean of 1, can represent a huge variation of rates, from practically 
invarient where the shape parameter β tends towards infinity to extreme rate heterogeneity when β 
approaches zero, and although other continuous distributions such as the log-normal have been 
explored (Golding, 1983), the gamma distribution is an established choice (Yang, 1994). We assume
that whilst the mutation rate is gamma distributed, the number of mutations in any one sequece is 
Poisson distributed; i.e. if the average mutation rate per site is αμ in a particular sequence, where 
alpha is gamma distributed and μ is the mean mutation rate, then the observed number of mutations 
is Poisson distributed with an expected number of mutations is lαμ where l is the number of 
nucleotides in the sequence. By assuming that the number of mutations is Poisson distributed weare 
assuming that they are rare and that they occur independently. Although, there is some evidence that
some mutations occur concurrently, because there is an excess of mutations that occur within 10bp 
on the same haplotype, these mutations still consititute a very small fraction of the total (~3%) 
(Schrider, Hourmozdi & Hahn, 2011).
We estimated the variation in the mutation rate within a mutational category (e.g. CpG transitions) 
as follows. Let us assume that the mutation rate at a site is αμ where μ is the mean mutation rate and 
 is a deviation from the mean that is taken from some distribution D(α), which has a mean of 1; in 
our analysis we assume that D(α;β) is a gamma distribution with a shape parameter . The number 
of mutations at a site can be modeled as a Poisson process for the reasons described above, and 
hence the number of mutations at a site is Poisson distributed. The probability of observing x 
mutations at a site is therefore
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which is the negative binomial distribution, where u=μk and k is a parameter proportional to the 
chance of observing a DNM; this is dependent upon the incidence and interest in the disease. The 
number of sites with x mutations is multinomially distributed and hence the likelihood of observing 
nx sites with x mutations is
L(u, )  n! G(x;u, )
nx
nx!x

(2)
where n is the total number of sites. We found the maximum likelihood values of the distribution 
using the Nelder-Mead algorithm as implemented in the NMaximize function in Mathematica 
(version 7). The model above is described for a single mutational category in a single gene. 
However, it is straightforward to expand the analysis across multiple mutational categories and 
genes. In each analysis each mutational category in each gene is allowed its own u parameter 
reflecting the fact that the chance of observing a mutation varies between genes, and that the rate of 
mutation varies between mutational categories. Confidence intervals on parameters were derived 
from the likelihood surface – i.e. by finding the parameter values that decreased the log-likelihood 
by 2 units.
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2.4 Results
2.4.1 Data
We have analysed DNMs in three genes that are associated with Mendelian disease. The genes are 
RB1, mutations in which cause retinoblastoma; we only consider mutations causing bilateral 
retinoblastoma since this disease is almost exclusively caused by a de novo germ-line mutation, 
whereas unilateral retinoblastoma is usually caused by somatic mutations. The second gene we 
consider is NF1, mutations in which cause neurofibromatosis type I. And the third gene is MECP2, 
mutations in which cause Rett’s syndrome. 
It is critical to our analysis that all mutations in a gene have similar penetrance, otherwise any 
apparent variation in the mutation rate might be due to variation in penetrance (i.e. a site with 
multiple recurrent DNMs might have a high mutation rate or the mutation might be highly 
penetrant). As a consequence we only consider nonsense mutations, and in RB1 and NF1 we only 
consider sites at which nonsense mutations are predicted to be caught by nonsense mediated decay 
(NMD). Furthermore, in RB1 we ignore data from the first exon because mutations in the first exon 
may display variable levels of penetrance due to alternative translation initiation sites (Sanchez-
Sanchez et al. 2007). All the nonsense mutations we consider in RB1 and NF1 should therefore 
have the same probability of being detected. The analysis of MECP2 is more complex because the 
vast majority of sites that could generate a nonsense mutation are in the last exon and hence would 
not be caught by NMD; hence some nonsense mutations, particularly those towards the end of the 
gene could be less penetrant than those earlier in the gene. Furthermore, it is possible that nonsense 
mutations in the second and third exons (first and second coding exons) are lethal and therefore not 
routinely observed. Figure 1 shows the distribution of DNMs along the MECP2 gene. It is 
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conspicuous that almost all pathogenic mutations occur between the start of the final exon and the 
end of the transcription repression domain. As a consequence we analysed two datasets for MECP2 
– all sites at which a nonsense mutations could occur, and all sites at which nonsense mutations 
could occur between the first and last sites that have multiple DNMs (sites 423 to 889 inclusive). 
Reducing the dataset in this manner does not alter the relative rates of mutation greatly, but it does 
reduce the evidence for heterogeneity within mutational categories (see below); this reduced dataset
can therefore be considered a conservative dataset.
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Figure 2.1. The distribution of nonsense DNMs and sites at which a mutation can cause a nonsense 
mutation in the MECP2 gene. The start of the last exon is marked. Crosses mark sites at which a 
mutation would generate a stop codon, filled circles mark sites at which nonsense DNMs have 
occurred and the number that have been observed.
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Table 2.1 gives the number of DNMs in each of four mutation categories, transitions and 
transversions at CpG sites, and transitions and transversions at non-CpG sites, and Appendix 2.1 
gives the number of sites hit by 0,1, 2…etc DNMs. We divided the data in this way because there 
are large differences in the rate of mutation of these mutational types (reviewed in (Hodgkinson & 
Eyre-Walker 2011). For each of our genes we have large numbers of nonsense DNMs. These are 
dominated by CpG transitions but we also have substantial numbers of non-CpG transitions and 
transversions.
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Table 2.1. The numbers of nonsense DNMs in each gene and mutational category for three disease 
genes. The MECP2 – restricted figures are for DNMs between positions 421 and 888. The Kong 
and Michaelson data are all the DNMs reported in Kong et al. (2012) and Michaelson et al. (2012) 
respectively.
CpG ts CpG tv non-CpG ts non-CpG tv
RB1 97 5 15 32
NF1 52 4 24 20
MECP2 253 0 6 12
252 0 2 10
Kong 855 73 2489 1516
Michaelson 70 10 282 185
MECP2 – restricted
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2.4.2 Heterogeneity between genes
It is of interest to know whether the frequencies of different types of mutation vary substantially 
between genes. Unfortunately, because of the way in which our data have been sampled we cannot 
answer this question directly – the rate at which DNMs are detected in our genes depends upon the 
frequency of the disease, the severity of phenotype and the interest of clinicians. However, we can 
compare the relative frequency of different types of mutation between genes and compare those 
between genes and to the genomic average. We test for differences between genes, and between 
genes and the genomic average using a chi-square goodness of fit test, fitting a model in which we 
assume the relative rates of mutation in the four mutational categories are the same in the two genes
(or genes and genome) (see the Materials and Methods section).
Two recent studies have obtained substantial numbers of DNMs from the complete genome 
sequencing of trios (Kong et al. 2012; Michaelson et al. 2012). Surprisingly the relative frequencies
of the four mutation types differ significantly between these studies (Table 2.2) (Chi-square 
goodness of fit test, Χ2=8, df=3, p=0.045). The difference seems to be largely a consequence of a 
higher relative rate of CpG transitions in the data of Kong et al. (Kong et al. 2012) compared to the 
data of Michaelson et al. (Michaelson et al. 2012) (28x the rate of non-CpG transversions versus 
19x) (Table 2.2). 
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Table 2.2. The rates of mutation expressed relative to the rate of transversion at non-CpG sites.The 
rates are derived by dividing the numbers of DNMs by the number of sites (Supp. Table S1), and 
then dividing the rate by the rate for non-CpG transversions.
CpG ts CpG tv non-CpG ts non-CpG tv
RB1 90 5.7 3.5 1
NF1 120 14 5.5 1
MECP2 640 0 4.8 1
240 0 1.5 1
28 2.4 1.6 1
19 2.7 1.5 1
MECP2 – restricted
Kong et al.
Michaelson  et al.
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The reason for this discrepancy is not clear; it may be due to different ages amongst the two 
cohorts, or different biases in the sequencing methods, as other analyses seem to suggest (Eyre-
Walker & Eyre-Walker 2014).
However, more striking than the difference between the two trio datasets are the differences in the 
relative rates of mutation between these datasets and the three genes for which we have DNMs 
(Table 2.2); each of the disease genes shows higher rates of mutation relative to the rate of non-CpG
transversion than trio datasets. The most dramatic difference is the relative rate of CpG transition 
mutation in the MECP2 gene where the mutation rate is estimated to be over 240x higher than the 
rate of non-CpG transversion (640x for the complete MECP2 dataset and 236x for the restricted 
dataset). Pairwise comparisons show that the patterns of mutation are highly significantly different 
between MECP2 and the other two genes (Chi-square goodness of fit tests: Χ2 > 99, df=6, p<0.001 
in both cases), but not between RB1 and NF1. The patterns are also highly significantly different 
between each of the three genes and both the datasets of Kong et al. and Michaelson et al. (Chi-
square goodness of fit tests: Χ2 > 86, df=3, p<0.001 in all cases). Unfortunately, it is not possible to 
say from these data whether the large relative rates are due to a low rate of mutation at non-CpG 
sites or a high rate at CpG sites. 
2.4.3 Heterogeneity within genes
The analyses above show that the relative frequency of different types of mutation varies between 
genes. We can also test whether the rate of mutation within each of these mutational types varies 
between sites within a gene. Using a chi-square test of heterogeneity (deriving the null distribution 
by randomisation) we find highly significant evidence of heterogeneity over the entire dataset 
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whether we consider all sites in the MECP2 gene or the restricted MECP2 dataset (p < 10-5) (Table 
2.3). Surprisingly we find significant homogeneity, not heterogeneity, for CpG transitions sites in 
the RB1 gene (i.e. mutations are more evenly distributed between sites than one would expect by 
chance alone). The data for this gene comes from three different labs. None of these datasets shows 
this excessive homogeneity individually and in fact the dataset from Barts Hospital shows 
marginally significant evidence of heterogeneity (p=0.081, null distribution derived by 
randomisation) (Appendix 2.2). The datasets are not significantly different to each other (Χ2=23.6, 
df=20, p=0.26) (Appendix 2.3). It therefore remains unclear why the combination of the three 
datasets leads to significant homogeneity. It seems most likely that has arisen by chance.
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Table 2.3. Testing for mutation rate heterogeneity within genes and mutational categories. The table
gives the probability of observing the distribution of DNMs across sites under the null hypothesis 
that sites are equally mutable. Probabilities were combined using the unweighted Z-method 
(Whitlock 2005). The data from individual genes are combined in a number of different 
combinations – with and without the MECP2 data, and with the restricted MECP2 data. The 
probabilities are combined for each mutational type, but also across genes and mutational types.
CpG ts CpG tv non-CpG ts non-CpG tv
RB1 0.999 0.0629 0.0969 0.0412
NF1 0.0052 0.0344 0.1312 0.6017
MECP2 <0.0001 - 0.1281 <0.0001
<0.0001 - 0.0997 <0.0001
0.65 0.0089 0.044 0.15
Overall (row above) 0.0087
0.032 0.0089 0.02 0.0013
Overall (row above)
0.032 0.0089 0.016 0.0013
Overall (row above)
MECP2 – restricted
Overall – without MECP2
Overall – MECP2 all
2.0 x 10-6
Overall -  MECP2 restricted
1.6 x 10-6
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The strongest evidence for heterogeneity comes from non-CpG transversions in the MECP2 gene. 
In the restricted dataset there are 38 sites at which a non-CpG transversion will generate a nonsense 
mutation and there are 10 DNMs that have occurred at these sites. However, 6 of the DNMs have 
occurred at one site (site 423); all of these are C>G changes even though a C>A would also 
generate a stop codon.
Using the heterogeneity analysis we can identify 3 sites that have mutation rates that are 
significantly above background levels (Table 2.4). The mutation rate at these sites relative to all 
other sites, of the same mutational type, in the respective genes are given in Table 2.4. For two of 
these sites the mutation rates are only modestly above background levels; this reflects the power 
that we have to detect significantly hyper-mutable sites in CpG transition sites because we have 
more data than in other mutational categories. However, in MECP2 we estimate that site 423, the 
site which has been hit by 6 non-CpG transversion DNMs has a mutation rate at least 150x (or 56x 
in the restricted dataset) higher than the background rate of non-CpG transversion in this gene. 
There is no obvious context effect associated with these sites (Table 2.4).
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Table 2.4. Significantly hypermutable sites. Numbers in parentheses in the rate column are the rate 
of the hypermutable site relative to the mean of all other sites; estimates for MECP2 are using the 
restricted MECP2 data. The nucleotide underlined in the context column is the hypermutable site.
Gene Mutation type Rate Context hg19 coordinates
MECP2 CpG transition 2.0 (1.5) chrX:153,296,777
MECP2 non-CpG transversion 150 (56) chrX:153,296,856
NF1 CpG transition 4 chr17:29,588,751
CCCCTCCCGGCGAGAGCAGAA
TGATTGCGTACTTCGAAAAGG
TGTTGGAAGACGACCTTTTGA
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2.4.4 Quantification
The estimates of the mutation rate at the sites with significantly elevated mutation rates are crude; 
one would expect that as more data accumulate so more sites will be found to be significantly 
hyper-mutable and hence the estimates of the rates will increase as sites are excluded from the 
background level. Therefore to better quantify the variation in the mutation rate we used maximum 
likelihood to fit a model in which mutation rates were distributed according to a gamma 
distribution. We fit several models in which the distribution of rates was shared (i) across all genes 
and mutational categories, (ii) across genes but varied between mutational categories, (iii) across 
mutational categories but varied between genes and (iv) finally a model in which every gene and 
mutational category combination had its own distribution. Using likelihood ratio tests we find the 
best supported model is one in which the gamma distribution is specific to a mutational category but
is shared across genes (Appendix 2.4). 
If we consider the shape parameter estimates for each mutational category it seems that CpG 
transitions have a much lower level of variation than the other mutational categories (higher the 
values of the shape parameter indicate lower levels of variation) (Table 2.5). In contrast the other 
three categories show substantial variation. To quantify this variation we calculated the ratio of the 
rates from the 90th and 10th percentiles. Whereas CpG transitions show just 1.4 fold variation 
between the upper and lower deciles the ratio for all the other categories is very substantial; for non-
CpG transitions there is 36-fold variation but for CpG transversions and non-CpG transversions we 
infer more than a 1000-fold variation. However, the confidence intervals on these individual 
estimates are large and are also compatible with modest levels of heterogeneity; this is due a lack of
data. We therefore combined data from CpG transversions, non-CpG transitions and non-CpG 
transversions.
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Table 2.5. Estimates of mutation rate heterogeneity within genes and mutational categories. 
Estimates of the shape parameter of the gamma distribution and the ratio of the upper and lower 
deciles of the distribution. 95% confidence intervals, as inferred from the likelihood surface, are 
given in brackets. cts – CpG transitions, ctv – CpG transversions, nts – non-CpG transitions, ntv – 
non-CpG transversions
Mutation type Shape Ratio of the rates of first and last deciles
cts 63 (13, infinity) 1.4 (2.1, 1.0)
ctv 0.39 (0.069, infinity)
nts 0.81 (0.26, infinity) 36 (8000, 1.0)
ntv 0.24 (0.11, 0.64)
ctv+ntv 0.26 (0.13, 0.64)
nts+ntv 0.39 (0.20, 0.91) 550 (93,000, 27)
ctv+nts+ntv 0.39 (0.21, 0.85) 550 (56,000, 32)
550 (7.7 x 1013, 1.0)
16,000 (6.1 x 1014, 70)
8000 (3.0 x 107, 70)
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 Our estimate of the shape parameter is 0.39 (0.21, 0.85) and this corresponds to a ratio of deciles of
550 (i.e. the top 10% of sites mutate at least 550x faster than the bottom 10% of sites) with 95% CIs
of 32x, 56,000x. In other words there appears to be very substantial variation in the mutation rate 
within each mutational category, with the exception of CpG transitions.
2.5 Discussion
We have provided evidence for two types of mutational heterogeneity. First, we have demonstrated 
that there is substantial variation in the relative rates of CpG and non-CpG mutations. The most 
conspicuous pattern is the very high rate of CpG transitions relative to non-CpG transversions. 
Whereas on average CpG dinucleotides undergo transition mutations between 18 and 30 fold the 
rate of non-CpG transversions, in our three Mendelian disease genes they undergo 90 to more than 
200-fold higher rates of mutation. It is not possible to infer whether this is due to a low rate of non-
CpG transversion or a high rate of CpG transition. Second, we have shown that there is significant 
heterogeneity in the mutation rate between sites within each mutational category. This is 
particularly evident for all categories other than CpG transitions; we estimate amongst the other 
categories that the mutation rate may vary by 100-fold or more.
Our conclusions are conditional on the assumption that all the mutations, which we have 
considered, both those that have occurred and those that could occur in a gene, are equally likely to 
be sampled. Variation in sampling might arise through three processes – variation in penetrance, 
alternative splicing and ascertainment bias. 
In an attempt to ensure that all mutation were equally penetrant we restricted our analysis to 
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nonsense mutations, and in the case of RB1 and NF1, to nonsense mutations that are predicted to be 
caught by NMD. In the case of MECP2 most sites that could cause a nonsense mutation are found 
in the last exon and hence would not be caught by NMD. In attempt to ensure that all mutations in 
MECP2 had similar penetrance we analysed the pattern of mutation both amongst all DNMs and 
amongst a subset of DNMs between the first and last recurrently hit sites. We have found similar 
patterns. If we remove MECP2 from our analysis we still find evidence that the ratio of CpG to 
non-CpG mutations varies between the two disease genes and the background rate, and there is still 
significant heterogeneity in the mutation rate within a mutational category (Table 3). Never-the-less 
it is difficult to completely rule-out variation in the level of penetrance as an explanation for our 
results; if the variation in the density of DNMs is due to variation in penetrance then our results 
suggest that penetrance varies considerably between mutational categories and between sites within 
a gene.
The apparent variation in the mutation rate could also be due to ascertainment bias. Although we 
restricted our analysis to data that had come from studies in which the same part of the gene had 
been analysed it is possible that the causative mutation was not ascertained and these cases 
discarded. If some mutations are more likely to escape detection than others then it will appear as 
though there is mutation rate variation.
The variation could also potentially be due to alternative splicing (or alternative translation start 
sites) since nonsense mutations in constitutive exons might be more penetrant (or more lethal) than 
nonsense mutations in alternatively spliced exons. However, this seems an unlikely explanation for 
our results. RB1 is known to have an alternative translation start site (Sanchez-Sanchez et al. 
2007) and as a consequence exon 1 was removed from the analysis. There are two major splice 
forms of MECP2 which differ in both their translation start site and the inclusion of exon 2 – variant
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1 includes exon 2, in which translation starts, whereas variant 2 excludes exon 2 with translation 
starting in exon 1 (Kriaucionis & Bird 2004). We have analysed data mapped to variant 1, which 
differs from variant 2 in the first 26 bp. Hence the variation we observe is unlikely to be a 
consequence of alternative splicing since the vast majority of the data we have analysed comes from
exons that are found in the major splice forms. There are multiple splice forms of NF1, although 
most of them yield products that are removed by NMD or result in highly truncated proteins 
(Barron & Lou 2011). We have used data that maps to transcript variant 2, which is one of two 
major splice forms. This differs from variant 1 in missing exon 31 (formerly exon 23a), a 21 amino 
acid exon, found in variant 1. So again it seems unlikely that alternative splicing can be responsible 
for our results in NF1 because we have analysed data only from the exons present in both of the two
major splice forms.
Another potential explanation for our results is positive selection in the germ-line. It has been found
that some pathogenic mutations are advantageous within the male germ-line leading to an increased 
prevalence of diseases such as Apert’s syndrome, which is caused by mutations in the gene FGFR2 
(Goriely & Wilkie 2012). None of the genes that we have studied are known to have mutations that 
are positively selected in the germ-line and it seems unlikely that the heterogeneity amongst 
nonsense mutations could be caused by this process, since all nonsense mutations are predicted to 
have the same or similar phenotypes.
The variation in the density of DNMs is therefore most likely due to variation in the mutation rate. 
It has previously been shown that mutation rates vary at a regional scale (reviewed in (Hodgkinson 
& Eyre-Walker 2011)). However, it has not been noted before that the relative rates of CpG and 
non-CpG mutation can vary substantially. The magnitude of the variation that we have observed 
might in part be due to the fact that genes with the highest mutation rates are those most likely to be
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associated with disease, assuming that the high CpG to non-CpG mutation rate reflects a high CpG 
mutation rate and not a low non-CpG rate. There is some evidence for this effect; a recent model of 
the mutation rate at sites in the human genome, based on the analyses of DNMs and where they 
occur, predicts that disease genes have higher rates of mutation than non-disease genes (Michaelson
et al. 2012). 
It has also been noted that the mutation rate can vary within a mutational category because of 
context (Hodgkinson & Eyre-Walker 2011)however the effects within CpG or non-CpG categories 
have been inferred to be quite modest. For example, Hwang and Green (Hwang & Green 
2004) estimated, using the divergence between primate species, that on average CCG, ACG, GCG 
and TCG mutate 24, 29, 18 and 23-fold faster than the genomic average. Context effects at non-
CpG sites are also fairly modest, typically showing 2-3 fold variation when the immediately 
adjacent nucleotides are considered (Hwang & Green 2004), getting progressively weaker as sites 
further away from the focal site are considered (Zhao & Boerwinkle 2002). The level of variation 
within all mutational categories except CpG transitions seems to be considerably greater than this. 
The substantial variation in the mutation rate within each mutational category, except CpG 
transitions, is consistent with the cryptic variation in the mutation rate, which was first identified in 
nuclear DNA from the coincidence of SNPs in humans and chimpanzees (Hodgkinson et al. 2009; 
Johnson & Hellmann 2011). As we have found here, Hodgkinson et al. (Hodgkinson et al. 
2009) estimated that there was more variation in the mutation rate within non-CpG sites, than 
within CpG-sites, and estimated that a gamma distribution with a shape parameter of 0.85 (0.83, 
0.87) fitted the data at non-CpG sites. This is not significantly different to the estimate obtained 
here, 0.39 (0.20, 0.91).
The variation at CpG sites could potentially be a consequence of variation in methylation. 
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Methylated CpGs are expected to mutate faster than non-methylated CpGs due to the instability of 
methyl-cytosine (Coulondre et al. 1978; Bird 1980; Sved & Bird 1990). None of the sequences that 
we have analysed contain CpG islands, regions of the genome in which CpGs are not methylated. 
However, some of the variation may be due to residual variation in methylation.
In summary we have shown that there is significant variation in the mutation rate both between and 
within genes. Some of this variation might explain why these genes are associated with disease; 
they have high mutation rates, either overall or at specific sites that can cause disease, and this 
makes it more likely that pathogenic mutations will recur in the human population and cause 
disease.
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3. Are sites with multiple single nucleotide variants in cancer
genomes a consequence of drivers, hypermutable sites or
sequencing errors?
3.1 Abstract
Across indepedent cancer genomes it has been observed that some sites have been recurrently hit by
single nucleotide variants (SNVs). Such recurrently hit sites might be either i) drivers of cancer that 
are postively selected during oncogenesis, ii) due to mutation rate variation, or iii) due to 
sequencing and assembly errors. We have investigated the cause of recurrently hit sites in a dataset 
of >3 million SNVs from 507 complete cancer genome sequences. We find evidence that many sites
have been hit significantly more often than one would expect by chance, even taking into account 
the effect of the adjacent nucleotides on the rate of mutation. We find that the density of these 
recurrently hit sites is higher in non-coding than coding DNA and hence conclude that most of them
are unlikely to be drivers. We also find that most of them are found in parts of the genome that are 
not uniquely mappable and hence are likly to be due to mapping errors. In support of the error 
hypothesis, we find that recurently hit sites are not randomly distributed across sequences from 
different laboratories. We fit a model to the data in which the rate of mutation is constant across 
sites but the rate of error varies. This model suggests that ~4% of all SNVs are error in this dataset, 
but that the rate of error varies by thousands-of-fold between sites.
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3.2 Introduction
There is currently huge interest in sequencing cancer genomes with a view to identifying the 
mutations in somatic tissues that lead to cancer, the so called “driver” mutations. Driver mutations 
are expected to cluster in particular genes or genomic regions, or to recur at particular sites in the 
genome, because only a limited number of mutations can cause cancer. For example, the driver 
mutations in the TERT promoter were identified because it had independently occurred in multiple 
cancers (Huang et al., 2013). However, there are two other processes that can potentially lead to the 
repeated occurrence of an apparent somatic mutation at a site. First, it is known that the mutation 
rate varies across the genome at a number of different scales in both the germ-line and soma 
(Hodgkinson & Eyre-Walker, 2011; Hodgkinson, Chen & Eyre-Walker, 2012; Michaelson et al., 
2012; Francioli et al., 2015). Sites with recurrent SNVs could simply be a consequence of sites with
high rates of mutations. And second there is the potential for sequencing error. Although, the 
average rate of sequencing error is thought to be quite low it is evident that some types of sites, such
as those in runs of nucleotides, are difficult to sequence accurately. Furthermore, since the genome 
contains many similar sequences it can often be difficult to map sequencing reads successfully 
(Treangen & Salzberg, 2013).
In the germ-line the density of point mutations varies at a number of different scales (Hodgkinson &
Eyre-Walker, 2011). At the mega-base scale the mutation varies by about 2-fold, and ~50% of this 
variance can be explained by correlations with factors such as replication time, recombination rate 
and distance from telomeres (as reviewed in (Hodgkinson & Eyre-Walker 2011)). However the 
greatest variance, reportedly up to ~30-fold, has been found at the single nucleotide level 
(Hodgkinson, Chen & Eyre-Walker, 2012; Kong et al., 2012; Michaelson et al., 2012), whereby the 
nucleotide context, that is the identity of the bases immediately 5’ and 3’ of the mutated base, are 
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highly influential on the rate of mutation (Gojobori, Li & Graur, 1982; Bulmer, 1986; Cooper & 
Krawczak, 1990; Nachman & Crowell, 2000; Hwang & Green, 2004). The most well known 
example is that of CpG hyper-mutation (Bird, 1980), which is thought to account ~20% of all 
mutations in the human genome (Fryxell & Moon, 2005). However there is also variation at the 
single nucleotide level that cannot be ascribed to the effects of neighbouring nucleotides; this has 
been termed cryptic variation in the mutation rate and is thought to account for at least as much 
variation in the mutation rate as does simple context (Hodgkinson, Ladoukakis & Eyre-Walker, 
2009; Eyre-Walker & Eyre-Walker, 2014, Johnson & Hellman, 2011, Smith et al., 2016).
The somatic mutation rate is estimated to be at least an order of magnitude greater than that of the 
germ line (Lynch, 2010). It has been shown to vary between cancers (Lawrence et al. 2013) and 
different cancer types are known to vary in their relative contributions of different mutations to their
overall mutational compositions (Alexandrov et al., 2013). For a review see (Martinocorena & 
Campbell, 2015). The aforementioned correlates of variation that are found in the germ line are also
apparent in the soma (Hodgkinson, Chen & Eyre-Walker, 2012; Schuster-Bockler & Lehner, 2012; 
Lawrence et al., 2013; Liu, De & Michor, 2013), for example replication time correlates strongly 
with single nucleotide variant (SNV) density at the 1Mb base scale and can vary by up to 3-fold 
along the genome (Hodgkinson & Eyre-Walker, 2011; Woo & Li, 2012). However, as yet there has 
been no attempt to quantify the level of cryptic variation in the mutation rate at the single nucleotide
level in the somatic genome. This is an important property to understand; for example a site which 
experiences a recurrence of SNVs across many cancer genomes would be of interest as a potential 
driver of cancer (Lawrence et al., 2013), however, this site might simply be cryptically 
hypermutable (Hodgkinson, Ladoukakis & Eyre-Walker, 2009; Eyre-Walker & Eyre-Walker, 2014; 
Smith et al., 2016). Here we examine the distribution of recurrent SNVs taken from 507 whole 
genome sequences made publicly available by Alexandrov et al. (2013) to investigate the level of 
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cryptic variation in the mutation rate for somatic tissues. We show that there is a large excess of 
sites that have been hit by recurrent SNVs. Since the density of these is greater in the non-coding, 
than the coding fraction of the genome, we conclude that most of them are unlikely to be drivers. 
We therefore investigate whether they are due to mutational heterogeneity or sequencing errors. In 
particular we investigate whether there might be cryptic variation in the mutation rate in cancer 
genomes. Unfortunately, the available evidence suggests that most sites with recurrent SNVs are 
likely to be due to sequencing error or errors in post-sequencing processing. 
3.3 Methods
3.3.1 Genome and data filtering
The human genome (hg19/GRCh37) was masked to remove  simple sequence repeats (SSR) as 
defined by Tandem Repeat Finder (Benson, 1999). The remaining regions were separated into three 
genomic fractions, consisting of 1,346,629,686 bp of non-coding transposable element DNA (TE), 
defined as LINEs, SINEs, LTRs and DNA transposons as identified by repeat masker (Smit et al. 
1996), 1,322,985,768 bp of non-coding non-transposable element DNA (NTE), and 119,806,141 bp 
of exonic non-transposable element DNA (EX) defined by Ensemble (Flicek et al., 2011). From the 
supplementary data of Alexandrov et al. (2013) we collated 3,382,737 single nucleotide variants 
(SNV), classified as “somatic-for-signature-analysis” (see (Alexandrov et al., 2013) for SNV 
filtering methods). These can be downloaded from 
ftp://ftp.sanger.ac.uk/pub/cancer/AlexandrovEtAl/. These came from 507 whole genome sequenced 
cancers and represent 10 different cancer types and were reduced to 3,299,881 SNVs when 
excluding SNVs in simple sequence repeates (SSRs); 1,666,759 in TE and 1,535,069 in NTE and 
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98053 in EX. 
3.3.2 Testing for mutation rate heterogeneity
We were interested in whether some sites have more SNVs than expected by chance. Since the 
mutation rate is affected by the identity of the neighbouring nucleotides we need to control for those
effects. To do this we separated each SNV into one of 64 categories based upon the triplet to which 
it was the central base. This was reduced to 32 triplets when accounting for base complementarity 
with the pyrimidine (C/T) taken as the central base. If the total number of triplets of type i (e.g. 
CTC in the non-TE fraction) is li and the number SNVs at that triplet is mi then the expected 
number of sites hit x times can be calculated using a Poisson distribution:
Ei ( x )=li P(x ,μ i) (1)
where  P ( x , μi )=
e−μi μ i
x
x !
is the Poisson distribution and μi = mi/li is the mean number of SNVs per 
site, The expected number of sites with x SNVs across all triplets was calculated by summing the 
values of Pi(x). Whether the observed distribution deviated from the expected was tested using a 
chisquare goodness of fit test; the chisquare value for   the observed n sites hit x times was 
calculated for each hit category (0-7 hits). The individual probabilities of observing n sites being hit
x times is derived from a Poisson distribution and is calculated for n=0 to n=max(n) for each hit 
category (0-7 hits). The total probability for observing the data for each hit category can then be 
calculated as 1-sum(individual probabilities for each hit category).
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3.3.3 Model fitting
As well as testing whether there was significant hetereogeneity we were also interested in 
quantifying the level of variation. We fit two basic models. In the first we allowed the density of 
SNVs to follow a gamma distribution. Let the expected density of SNVs at a site be μα where μ is 
the mean density of SNVs for a particular triplet and α is the deviation from this mean. This 
deviation is assumed to be gamma distributed, D(α;β), parametrized with a shape parameter of beta 
and a mean of one. Under this model the expected number of sites with x SNVs is 
Ei(x ;β)=li∫
0
∞
D(α ;β)P(x ,αμi)dα (2)
In a second model we imagine that the production of SNVs depends upon two processes, one of 
which is constant across sites, and one which varies across sites, with the rate, α, drawn from a 
gamma distribution. Let the proportion of SNVs due to the first process be ε. Then the rate at which 
SNVs occur at a particular site where the rate of α is μiε + αμi(1−ε). Hence the expected number of 
sites with x SNVs is
Ei(x ;β ,ε)=li∫
0
∞
D(α ;β)P(x ,μ i(ε+α(1−ε)))d α (3)
We can now sum across triplets to find the expected number of sites with x SNVs.
E(x )=∑
alli
Ei(x ;β ,ε) (4)
Since sites with SNVs are rare, the number of sites with x SNVs is approximately Poisson 
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distributed. Hence if we observe E^(x ) sites with x SNVs the likelihood can be written as 
L=∏
x=1
∞
P( E^(x ), E( x)) (5)
These likelihoods can be multiplied across triplets to obtain the overall likelihood. We estimated the
maximum likelihood values of the model parameters using the NMaximize function of 
Mathematica (version 7) which implements the Nelder-Mead algorithm (Nelder et al., 1965). 
Chisquare goodness of fit test, as described in section 2.3.3 was used to compare the fit expected 
number of sites with x SNVs obtained by the models to the observed data.
3.3.4 Privacy analysis
To investigate whether the SNVs at some sites tended to be produced by a particular research group 
we took all sites with 3 or more SNVs from the same cancer type and then performed Fishers exact 
test on a 2 x 30 matrix using the the R stats package, version 3.2.4 (R Core Team, 2016). 
3.3.5 Mappability
Each nucleotide in genome was assigned a mappability score for uniqueness, as determined by the 
Mappability track (Derrien et al., 2012) downloaded from the UCSC table browser at 
http://genome.ucsc.edu/ (Karolchik et al., 2004). This feature assigns a value of 1 to unique k-mer 
sequences in the genome, 0.5 to those that occur twice, 0.33 to those that occur thrice etc. This is 
computed for every base in the human genome with the value being assigned to the first position of 
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the k-mer. We used k-mers of 100 and 20 bases.
3.4 Results
3.4.1 The distribution of recurrent SNVs
If there is no variation in the density of single nucleotide variants (SNVs) then we should find them 
to be distributed randomly across the genome. To investigate whether this was the case we 
calculated the expected number of sites with 1,2,3…etc SNVs, taking into account the fact that 
some triplets have higher mutation rates than others. We found that there are some sites that have 7 
SNVs whereas we expect very few sites to have more than 3 SNVs (Table 3.1A, Figure 3.1) – the 
difference is highly significant using the Chi-square goodness of fit test (p < 0.0001) for both the 
whole genome (Total) and when separating the genome into non-coding transposable elements 
(TE), non-coding non-transposable elements and (NTE) and exons (EX) (Table 3.1A).  We refer to 
sites with 3 or more SNVs as excess sites. In total we observed 1187 excess sites (Table 3.1A) with 
the density of excess sites in TE being 3.9 and 3.4 fold greater than in NTE and EX respectively. 
The probability of this level of SNV recurrence by chance alone is so low (Chi-squared goodness of
fit test, p < 0.0001) that these excess sites must either be (i) drivers, (ii) the result of mutation rate 
heterogeneity across the genome or, (iii) the consequence of next generation sequencing (NGS) 
pipeline errors.
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Table 3.1. Observed and expected values for the distribution of SNVs for sites hit from 0-7 times. 
A) shows data for the whole interrogable human genome, excluding simple sequence repeats. B) 
shows data for all bases in the genome that are uniquely mappable at 100 base pairs. C) the same as 
B but for 20 base pairs. P < 0.001 for observing >7  sites with 3 SNVs in A),B) and C).
A) – All Sites
Site Type 0 hits 1 hit 2 hits 3 hits 4hits 5hits 6hits 7hits
Non-Exon TE obs (TE) 1344972042 1649680 7034 762 130 26 9 3
Non-Exon TE exp (TE) 1344964359 1663896 1430 1.14 9E-04 7E-07 5E-10 4E-13
Non-Exon Non-TE obs (NTE) 1321454397 1527967 3171 188 35 6 2 2
Non-Exon Non-TE exp (NTE) 1321451907 1532655 1206 0.86 6E-04 4E-07 3E-10 2E-13
Exon obs (EX) 119708384 97488 245 23 0 0 1 0
Exon exp (EX) 119708145 97939 57 0.03 2E-05 7E-09 3E-12 1E-15
Total obs 2786134823 3275135 10450 973 165 32 12 5
Total exp 2786124411 3294490 2692 2.04 2E-03 1E-06 8E-10 5E-13
B) – Mappable 100
Site Type 0 hits 1 hit 2 hits 3 hits 4hits 5hits 6hits 7hits
Non-Exon TE obs (TE) 1223239922 1517676 3927 266 25 11 5 1
Non-Exon TE exp (TE) 1223236637 1523873 1322 1.07 9E-04 7E-07 5E-10 4E-13
Non-Exon Non-TE obs (NTE) 1276165087 1499761 2698 97 16 2 0 1
Non-Exon Non-TE exp (NTE) 1276163336 1503124 1201 0.88 6E-04 5E-07 3E-10 2E-13
Exon obs (EX) 112360615 93084 185 16 0 0 0 0
Exon exp (EX) 112360453 93392 55 0.03 2E-05 7E-09 3E-12 1E-15
Total obs 2611765624 3110521 6810 379 41 13 5 2
Total exp 2611760426 3120389 2578 2 2E-03 1E-06 8E-10 6E-13
C) – Mappable 20
Site Type 0 hits 1 hit 2 hits 3 hits 4hits 5hits 6hits 7hits
Non-Exon TE obs (TE) 388613299 480820 741 9 0 0 0 0
Non-Exon TE exp (TE) 388612958 481494 417 0.34 3E-04 2E-07 2E-10 1E-13
Non-Exon Non-TE obs (NTE) 892370709 1061716 1621 31 4 1 0 1
Non-Exon Non-TE exp (NTE) 892369874 1063340 868 0.65 5E-04 3E-07 2E-10 2E-13
Exon obs (EX) 74735962 61034 103 6.00 0 0 0 0
Exon exp (EX) 74735883 61187 36 0.02 9E-06 4E-09 2E-12 7E-16
Total obs 1355719970 1603570 2465 46 4 1 0 1
Total exp 1355718714 1606021 1321 1 8E-04 6E-07 4E-10 3E-13
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It seems unlikely that the majority of the excess sites are due to drivers since the density of excess 
sites is higher in the TE and NTE parts of the genome than in EX (Table 3.1A). Furthermore, to date
only one intergenic driver of cancer – an activating C>T mutation in the TERT promoter (Huang et 
al. 2013) at chr5:1,295,228 – has been confirmed, and although this is included in the excess sites 
with 7 SNVs, the remaining 1186 excess sites are unlikely to be under such selection. It therefore 
seems likely that the excess sites are either due to mutation rate variation or problems with 
sequencing.
3.4.2 Excess sites are enriched in non-unique sequences
The human genome contains many duplicated sequences particularly within transposable elements, 
and these pose challenges for accurate alignment of the short ~100bp reads produced from NGS 
(Zhuang et al., 2014). If the excess sites were the result of NGS mapping errors then we might 
expect them to occur in regions of the genome that were hard to align. Using the mappability scores
(Derrien et al., 2012) we excluded all bases that were not uniquely mappable at 100bp; this should 
give an overall indication of how easy it is to map reads to the region. This only reduced the 
interrogable genome by 6%, but the number of excess sites was reduced by 64% (Table 3.1B), 
demonstrating that a large proportion of the excess sites were  in duplicated sequences and therefore
likely originate from mapping errors. However, even with this large reduction in excess sites we 
still observed many excess sites far greater than chance expectation (Chi-squared goodness of fit 
test, p < 0.0001) (Table 3.1B & Figure 3.1).
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Figure 3.1.  The number of sites with 0-7 SNVs per sites for: Main = all data, M100 = sites that are
uniquely mappable at 100 base-pairs, M20 = sites that are uniquely mappable at base-pairs and, 
Expected is the expected number of SNVs per site drawn from a poisson distribution using all data.
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The SNVs in this data were all called from >100bp reads. If the excess sites were errors of read 
mapping, they should not be affected by the uniqueness of shorter sequences (i.e. there is no reason 
why 100bp sequences that map uniquely to the genome should be mis-mapped if it contains a non-
unique 20bp sequence), however if the SNVs were the product of a biological process that was 
more prevalent in non-unique or repetitive sequences, then we might expect to see a reduction of 
excess sites when we exclude all bases that do not map uniquely at 20bp. When we excluded all 
bases that were not unique at 20bp we found that the interrogable genome was reduced by 52% and 
the excess sites were reduced by 96% (Table 3.1C & Figure 3.1). It is worth noting that, due to their
proliferative nature throughout the genome, this reduction disproportionately affects TEs where the 
interrogable genome is reduced by 71% and the excess sites by >99%. This would suggest that the 
excess sites existing in sequences that were unique at 100bp but not unique at 20bp may represent 
some biological process and not error. Furthermore, the TERT promoter, whose recurrence is the 
result of positive selection, and is therefore the only excess site that that we can confidently say is 
not a product of error, remains in this most conservative of these analyses. Despite this large 
reduction in excess sites, significant heterogeneity still remains; the probability of observing the 52 
excess sites in the part of the genome uniquely mappable at 20 bases is still extremely low (Chi-
squared goodness of fit test, p < 0.0001).
One other potential problem with mapping reads to non-unique sequences occurs when a segmental 
duplication has been collapsed in the assembly of the reference genome; i.e. reads from two 
different locations are mapped to the same locus in the reference. Differences between the 
duplications will appear as SNVs. If this was the case we would expect to see an increase in excess 
site read coverage of ~2-fold or greater. To investigate whether this could be a problem in our data 
we compared the read coverage for excess sites and non-excess sites, which nevertheless had an 
SNV, in the one set of cancer genomes for which we had this information - the liver cancers  
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sequenced by the RIKEN group. However, we found that the median read coverage for the excess 
sites (n=15) was actually lower than for non-excess sites (n=224602) (28 and 33 reads respectively; 
Mann-Whitney U test, p = 0.043)
3.4.3 Privacy of mutations
To further investigate the origin of excess sites we exploited the fact that some types of cancer were 
sequenced by different laboratories using different technologies and NGS pipelines. If the SNVs at 
excess sites found in a particular cancer are due to hypermutable sites then we would expect them to
be randomly distributed across research groups (i.e. all research groups should identify the same 
hypermutable sites). If however the SNVs at excess sites are due to error then we might expect them
to be heterogeneously distributed across research groups (i.e. the calling of recurrent false positive 
SNVs should be systematic of individual research group NGS pipelines). The liver cancers, which 
were all virus associated hepatocellular carcinomas, , were sequenced by two different groups; 66 
from the RIKEN group using the Illumina Genome Analyser (https://dcc.icgc.org/projects/LIRI-JP) 
and 22 from the National Cancer Centre in Japan using the IIlumina HiSeq platform 
(https://dcc.icgc.org/projects/LINC-JP). We found that the excess SNVs were heterogeneously 
distributed amongst research groups (Fisher's exact test, P = 4x10-6) suggesting that the 30 excess 
sites from liver cancers were predominantly errors (Appendix 3.1). 
3.4.4 Parameter estimation
To gauge how much variation there is in the density of SNVs across the genome we fit two models 
to the data using maximum likelihood. In model 1 we allowed the density of SNVs to vary between 
sites according to a gamma distribution, estimating the shape parameter, and hence the amount of 
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variation there was between sites. We fitted two versions of this model. In the first version, 1a, we 
constrained the model such that the mean SNV density, shape parameter, and hence the level of 
variation, was the same for all triplets. In the second version, 1b, we allowed the mean SNV density
and shape parameter to vary between triplets. The second of these models fits the data significantly 
better than the first according to a likelihood ratio test suggesting that the level of variation differs 
between triplets (Table 3.2). However, a goodness of fit test, comparing the number of sites 
predicted to have 1, 2, 3…etc SNVs per site to the observed data, suggests the model fits the data 
poorly. We therefore fit a second pair of models in which we allowed the rate of SNVs to be due to 
two processes. The first process, is constant across sites whereas the second process is variable and 
drawn from a gamma distribution. There are two parameters in the model, the proportion of SNVs 
at a site produced by the first process and the level of variation in the second process. This model 
might represent a situation where the rate of mutation is constant across sites but the rate of 
sequencing error is variable. As with the first model we fit two versions of this model; in Model 2a 
we constrained the model such that the parameters of the two processes were the same for all 
triplets. In Model 2b they were allowed to vary between triplets. Both models 2a and 2b fit the data 
significantly better than models 1a and 1b, and of this second pair of models, model 2b, which 
allows the parameters to vary between triplets fits the data significantly better than model 2a, in 
which the parameters are shared across triplets (Table 3.2). The best fitting model is therefore one in
which we have two processes contributing to the production of SNVs, one that is constant across 
sites, although it differs between triplets, and one which is variable across sites. Although, we can 
formally reject this model using a goodness-of-fit test (Chi-square p < 0.0001), because we have so 
much data, it is clear that the model fits the data fairly well (Figure 3.2). Under this model we 
estimate that approximately 4.1%, 2.8% and 4.2% of SNVs are due to the process that varies across 
sites in the TE and NTE, and EX sequences respectively. 
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Table 3.2. The fit of 4 models to the observed distribution of recurrent SNVs in the three different 
genomic fractions A) TE, B) NTE and C) EX. N = number of parameters. Italics indicate the best fit
as determined by a liklihood ratio test.
Figure 3.2. The fit of the observed recurrent SNV distribution to expected distribution under the 
favoured model, 2b, for A) TE, B) NTE and C) EX genomic fractions.
Model N Log-likelihood Shape
1a 2 -269283 0.13
1b 64 -2936 0.12
2a 3 -266889 0.00021 0.956
2b 96 -1302 0.00016 0.959
Non-Exon Non-TE (NTE)
Model N Log-likelihood Shape
1a 2 -227728 0.31
1b 64 -1207 0.37
2a 3 -227026 0.00039 0.963
2b 96 -566 0.00026 0.972
Exon (EX)
Model N Log-likelihood Shape
1a 2 -13878 0.18
1b 64 -270 0.22
2a 3 -13842 0.00019 0.966
2b 96 -240 0.00035 0.958
Median ε
Median ε
Median ε
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However, the variation in the density between sites due to the variable process is extremely large. 
The median shape parameters are 0.00016, 0.00026 and 0.00035 for the TE and NTE, and EX 
sequences respectively. Under a gamma distribution with a shape parameter of 0.0004 we would 
expect more than 99% of sites to have no SNVs generated by this variable process, but some sites to
have a density of SNVs that is 30,000-fold above the average rate. 
Discussion.
Through our analysis of ~3 million SNVs from whole cancer genomes we have shown that there are
many sites at which there is a significant excess of SNVs. The majority of these are unlikely to be 
drivers because the density of sites with an excess of SNVs is greater in the non-coding part of the 
genome than in the exons. It therefore seems likely that the majority of the excess sites are either 
due to hypermutation or problems with sequencing or the processing of the sequences. Several lines
of evidence point to sequencing problems being the chief culprit. First, many of the excess sites 
disappear when regions of the genome with low mappability are removed. Second, SNVs at a 
particular excess site tend to be found within the sequences from a particular laboratory; for 
example, site 85,091,895 on chromosome 5 has 5 SNVs in liver cancers, but all of these are found 
in the sequences from RIKEN not the sequences from the NCC. It is possbile that this could be 
caused by biological differences between the cohorts, either environmentally induced or 
endogenous genetic variation, such as that seen between European and African populations and the 
differing frequency of  5’-TCC-3’ > 5’-TTC-3' mutation (Harris, 2015). However the level of site 
and cohort specific, but cryptic, variation required would be huge and we have very little evidence 
to support such a hypothesis. Third, the level of variation in the density of SNVs is much greater 
than has been observed or suggested for variation in the mutation rate (Hodgkinson & Eyre-Walker, 
2011; Kong et al., 2012; Michaelson et al., 2012) though see a recent analysis of de novo germ-line 
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mutations which suggests there could be extreme mutational heterogeneity (Smith et al., 2016); 
some sites are estimated to have rates of SNV production that are tens of thousands of times faster 
than the genomic average. 
Only one line of evidence suggests that there might also be substantial variation in the mutation rate
as well as variation in the error rate. When we eliminate sites that are not uniquely mappable at 
20bp we find a great reduction in the number of excess sites relative to the case when we remove 
sites that are not uniquely mappable at 100bp, and yet the read length is greater than 100bp in the 
data that we have used. This might suggest that there are some repetitive sequences that are prone to
a process of hyper-mutation. However, it might also be that mappability at 100bp is not a good 
guide to mappability during sequence processing. First, some level of mismatch must be allowed 
during the mapping of reads to the reference because there are single nucleotide variants 
segregating in the population and there are somatic mutations in cancer genomes. Second, the 
mappability score is assigned to the first nucleotide of the k-mer that can be mapped. Third, 
although the read length was greater than 100bp, some shorter reads may have been used. Next 
generation sequencing involves a number of biological processes, such as the polymerase chain 
reactions in the pre-sequencing creation of libraries and the polymerization of nucleotides during 
sequencing by synthesis, any one of which can result in technology-specific sequencing artefacts 
(Quail et al., 2008; Nazarian et al., 2010), in addition to the considerable post-sequencing 
processing, such as filtering and mapping, which can also generate errors (Harismendy & Frazer, 
2009; Minoche, Dohm & Himmelbauer, 2011). Unfortunately it is not possible to say which of 
these factors is most important. 
We have fit two models to the data in which the density of SNVs varies across sites. In the first we 
imagine that the variation is due to a single variable process and in the second we imagine it is due 
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to two processes, one of which is constant across sites and one which is variable. We find that this 
second model fits the data much better than the first model, although it can be formally rejected by 
a goodness-of-fit test. In this second model we estimate the proportion of SNVs that are due to the 
two processes and the level of variation. We estimate that approximately 2.8-4.2% of SNVs are due 
to the second process and that this second process is highly variable between sites, such that a few 
sites have a density of SNVs that is ten of thousands higher than the average density. It is possible 
that the first process is mutation and the second is sequencing error, but we cannot rule out the 
possibility that the second process includes variation in the mutation rate as well. Studies of germ-
line (Hodgkinson & Eyre-Walker, 2011; Michaelson et al., 2012) and somatic (Hodgkinson, Chen 
& Eyre-Walker, 2012; Woo & Li, 2012; Lawrence et al., 2013; Liu, De & Michor, 2013; Polak et 
al., 2015) mutations have indicated that the mutation rate varies between sites on a number of 
different scales. However, indications are that the variation is probably fairly modest (Hodgkinson, 
Chen & Eyre-Walker, 2012; Michaelson et al., 2012). 
A model including two processes fits the data well (figure 2). However, e can reject this model in a 
goodness-of-fit test, because we have a huge amount of data. Possible reasons for the less than 
perfect fit include large scale variation in the mutation rate (Hodgkinson & Eyre-Walker, 2011; 
Schuster-Bockler & Lehner, 2012; Makova & Hardison, 2015) and multi-nucleotide-mutations 
(MNMs) (Rosenfeld, Malhotra & Lencz, 2010; Schrider, Hourmozdi & Hahn, 2011; Harris & 
Nielsen, 2014); the latter  represent ~2% of all human single nucleotide polymorphisms (SNPs) 
In conclusion it seems likely that many sites in somatic tissues that have experienced recurrent 
SNVs are due to sequencing errors or artefacts of post-sequencing processing and there seems to be 
little evidence of cryptic variation in the somatic mutation rate. However, this not necessarily mean 
that such variation does not exist – it would be extremely difficult to detect it given the high level of
site-specific sequencing error. As sequencing technology and processing pipelines improve in 
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accuracy, we would expect similar future analyses to be able to confidently estimate the true 
underlying variation in the somatic mutation rate. Accompanied by the flow of data from projects 
such as the 100k genomes project, it should soon be possible to achieve per triplet mutation rate 
variation map for individual cancer types and not just pooled across multiple cancers.
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4. Mutation rate variation is not associated with common
fragile site expression.
4.1 Abstract
Aphidiclolin-induced common fragile sites (aCFS) are large genomic regions that recurrently 
appear as breaks on metaphase spreads. They have been shown to coincide with regions of large-
scale genomic instability that are susceptible to copy number variants and inter-chromosomal 
rearrangements. Small mutations (SM), such as point mutations and small insertions and deletions 
are also ubiquitous in cancer genomes, representing the genomic instability and mutational 
processes within the cancer. The occurrence of both of these processes have been linked to 
replication stress;  One consequence of replication stress is replication fork breakage followed by 
attempts to restart replication using the homologous recombination machinery, which can remain 
error prone after restart. We hypothesised that the genomic instability at aCFSs in cancers could 
result in broken replication forks, followed by error prone replication restart and thus an increase in 
SMs at these loci. To investigate this we analysed the distribution of >3 million SMs from 507 
whole cancer genomes in aCFSs and non-fragile regions. We found no strong evidence to indicate 
that aCFSs are enriched in SMs beyond the expected influence of replication time, and thus 
conclude that the biological processes contributing to these different forms of large-scale and small-
scale mutation, are unlikely to be linked and may suggest that, while replication fork breakage is a 
feature of loci prone to fragility, replication fork restart may besuppressed at these loci.
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4.2 Introduction
Fragile sites (FS) are unstable, mega-base-long genomic regions that recurrently appear as breaks 
on metaphase spreads. The first fragile site described was found on chromosome 9 in blood cultures
in 1965 (Dekaban 1965). In 1984, aphidicolin, an agent of replication stress, was shown to induce 
repeated chromosomal breaks at specific locations in lymphocytes, and the term common fragile 
site (CFS) was coined (Glover et al. 1984). Recent work, mostly carried out in lymphocytes, has 
uncovered many features associated with CFSs (reviewed in (Debatisse et al. 2012; Ozeri-Galai et 
al. 2012; Durkin & Glover 2007)). They are reported to be associated with high AT content, to 
occur in late replicating regions (Letessier et al. 2011; Le Tallec et al. 2011) and to co-localise with 
large genes or transcription units (Le Tallec et al. 2013; Smith et al. 2006; Wilson et al. 2015). 
Loci associated with CFSs are also prominent in cancer etiology. They have been implicated in the 
reduced expression of overlapping tumour suppressor genes (Smith et al. 2006), are associated with 
large-scale mutagenic events in tumours, including large insertions and deletions and inter-
chromosomal rearrangements, and are prone to display copy number variations (CNVs)(Beroukhim 
et al. 2010; Bignell et al. 2010; Gao et al. 2014). Such genomic rearrangements can be broadly 
classified into those that result from non-allelic homologous recombination between relatively 
extensive (>100bp) regions of sequence identity and those that display no homology or limited 
microhomology at the their breakpoint junctions (Liu et al. 2012). The formation of CNVs, both in 
the germline (Lee et al. 2007) and in somatic tissues such as cancer (Arlt et al. 2011) has been 
linked to replication problems.
Single nucleotide variants (SNVs) or small insertions/deletions (<100 base pair indels) – 
collectively referred to hereon as small mutations (SM) - are also ubiquitous in cancer genomes. 
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Most SM are considered to be “passengers” or “noise” and represent unselected mutational 
processes of unstable genomes (Alexandrov et al. 2013; Lawrence et al. 2013; Stratton et al. 2009). 
The rate at which SNVs arise varies massively between cancers (Lawrence et al. 2013), and across 
the genome the variation in SNV density is known to correlate with GC content, replication time, 
distance to telomeres and histone modifications (Hodgkinson et al. 2012; Schuster-Bockler & 
Lehner 2012). However, these established correlations are only able to account for 40-60% of the 
variation observed (Hodgkinson et al. 2012; Hodgkinson & Eyre-Walker 2011; Schuster-Bockler & 
Lehner 2012) with replication time reported as the dominant correlate (Liu et al. 2013; Woo & Li 
2012; Koren et al. 2012). Although indels have been understudied in this area, likely due to 
technological difficulties in detection (Jiang et al. 2015; Mullaney et al. 2010), germ-line studies 
have shown that their density along the genome varies in a similar fashion to SNVs, with hot-spots 
exhibiting elevated indel rates up to 24-fold greater than the regional average (Mills et al. 2006) and
contribute to a similar level of genetic variation as SNVs (Mullaney et al. 2010; Mills et al. 2011). 
Most of the models that have been proposed to explain the origin of CFSs and large chromosomal 
rearrangements propose that replication has been compromised as a result of either DNA secondary 
structure (Walsh et al. 2013) or clashes between replication and transcription (Wilson et al. 2015). 
Because there is a paucity of origins associated with CFSs, this has been proposed to result in 
replication-associated DNA structures that are prone to recombination. Recombination mediated 
replication restart events in model organisms have been demonstrated to result in both non-allelic 
homologous recombination (Lambert et al. 2005; Lambert et al. 2010) and, even when restart 
occurs at the correct locus, in error prone replication (Deem et al. 2011; Sakofsky et al. 2015; 
Mizuno et al. 2012). Errors resulting from homologous recombination-restarted replication include 
template switching events, replication slippage at microhomology (Deem et al. 2011) and a variety 
of other SMs. Such errors have been proposed to underpin the etiology of a number of human 
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genetic disorders (Hastings et al. 2009). Currently, there have been no reports of an association 
between CFSs and SMs in cancer cells, despite the fact that both CFSs and SMs are associated with 
genomic instability and replication time in cancers. We hypothesize loci associated with aphidicolin
induced CFSs (aCFS) would be enriched in SMs in cancer samples. To this end, we examined the 
density of SMs from 507 human cancer whole genomes in aCFS and non-FS regions. 
4.3 Methods
4.3.1 Replication timing data and dividing the genome into 100 kilo-base windows
We downloaded Encode Repli-seq wavelet smoothed signal data (Thurman et al. 2007; Hansen et 
al. 2010) aligned to the reference genome (HG19/GRCh37) for the GM12878, HeLa, HUVEC, 
K562 and HepG2 cell lines from the UCSC ftp site 
ftp://hgdownload.cse.ucsc.edu/goldenPath/hg19/database/ to represent a wide range of cell types. 
The GM12878 cell line is an Epstein-Barr virus infected B-lymphocyte cell derived from female 
blood tissue with a normal karyotype,  the HeLa cell line is from a cervical carcinoma, the HUVEC 
cell line is derived from human umbilical vein endothelial cells with a normal karyotype, the K562 
cells were established from the blood tissue of a female with leukaemia, and the HepG2 cells are 
derived from the liver tissue of a male with hepatocellular carcinoma 
(http://genome.ucsc.edu/encode/cellTypes.html). We computed the mean replication time for 
chromosomes 1-22 and X in non-overlapping 100 kilo-base windows across 5 cell lines (GM12878,
HeLa, HUVEC, K562, HepG2) for correlations with SNV densities. We used the Repli-seq start 
coordinates for each chromosome (bp 24500) to denote the beginning of the first window. 
Chromosome Y was not included as no replication time data was available. Any windows 
83
containing unknown bases (denoted as N in the reference genome) were excluded from the analysis.
This resulted in 28,080 100 kilo-base windows.
4.3.2 Mutation densities
SNVs were taken from publicly available somatic mutations called from 507 whole genome 
sequences (Alexandrov et al. 2013) at 
ftp://ftp.sanger.ac.uk/pub/cancer/AlexandrovEtAl/mutational_catalogs/genomes. The initial 
3,382,737 SNVs were filtered to exclude those for which no replication time data existed, including 
those on the Y chromosome to produce a final count of 3,348,815 SNVs used in the analysis. 
214,058 indels were taken from 265 whole genome sequences from the same source as the SNVs 
and subjected to the same filters, resulting in a total of 210,314 indels used in the analysis. Indel and
SNV densities for each 100 kilo-base window were calculated as the total number of mutations in 
that window divided by the number of genomes (507 for the SNVs and 265 for the indels). No 
correction for unannotated bases was required as any windows with an unannotated base were 
removed from the analysis.
4.3.3 Compiling fragile sites
Four fragile site datasets were collated from i) Mrasek et al. (2010) (Mrasek et al. 2010) (henceforth
referred to as MRA), ii) Lukusa & Fryns (2008) (Lukusa & Fryns 2008) (henceforth referred to as 
LUK), iii) Le Tallec et al. (2013) (Le Tallec et al. 2013), (henceforth referred to as LET) and iv) 
Bignell et al. (2010) (Bignell et al. 2010) (henceforth referred to as BIG). Genomic coordinates for 
BIG were taken from the refined mapping position in their supplemental data and converted to 
HG19 from HG18 using the lift over utility available from University of California, Santa Cruz at 
http://genome.ucsc.edu/ (Hinrichs et al. 2006). LET, LUK and MRA HG19 genomic coordinates 
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were obtained directly from cytoband information listed in each respective publication. Only BIG, 
LUK and LET were considered for the aphidicolin-induced fragile site (aCFS) analysis as most 
MRA FSs occur at a low frequency. The inverse of the MRA coordinates were used in the 
classification of non-FS regions. Due to the low resolution to which FS are mapped, each 100 kilo-
base window was only classified as being contained within a FS if the whole window resided inside
the FS coordinates. Non-FS windows were those that were non-FS in all four datasets. 
4.3.4 Statistical analysis. 
The R stats package, R version 3.3.0, was used for all statistics (R Core Team 2016). To compare 
SNV and indel densities between various test and control data, median densities were used and 
significance was tested using the Mann-Whitney test. Differences in replication time between 
datasets were also tested using the Mann-Whitney test. Spearman's rank correlation was used to test
for associations between replication time and SNV density for the each of the K562 aCFSs. Linear 
and Quadratic regressions were modelled using the “lm” function with replication time as the 
predictor and SNV density as the response, the best fitting model was selected by the lowest AIC 
value. A t-test was used to test if the SNV densities in the latest replicating deciles of the non-FS 
control and aCFS tests were significantly similar.
4.4 Results
4.4.1 Classifying fragile sites
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In trying to assess the density of SM at loci that are representative of fragile sites (FS), the first 
challenge is to define what genomic regions are considered to be FS. Investigations in cells other 
than lymphocytes (Le Tallec et al. 2011; Le Tallec et al. 2013) and experiments with other inducers 
of FSs, such as 5-Azacytidine and BrdU (See (Baskaran & Brahmachari 2000) for a review) 
produce varying classifications of FSs. For example, data from one study (Mrasek et al. 2010), 
which includes infrequently expressed aphidicolin induced FSs, would estimate that ~66% of the 
genome is fragile. We therefore consider only aphidicolin induced common fragile sites (aCFS) 
with a break frequency of >1% for further analysis. However, even within this definition, multiple 
studies have produced different lists of aCFSs. We therefore investigate three possible aCFS 
datasets, each with their own merits; i) the LUK dataset (Lukusa & Fryns 2008) which compiled the
largest collection of 76 aCFSs in lymphocytes, covering ~16% of the genome, ii) the BIG dataset 
(Bignell et al. 2010) which compiled data on high resolution FISH mapping of 38 aCFSs covering 
~7% of the genome, and iii) the LET dataset (Le Tallec et al. 2013) which compiled 50 aCFSs 
across 9 different tissue types covering ~12% of the human genome. Each of the data sets; LUK, 
BIG and LET, contain aCFSs that are not only private to that data set but also shared across 
datasets, therefore direct comparison between datasets is not simple. Additionally the higher 
resolution mapping of the BIG data means that it is not directly comparable to the LUK and the 
LET data. We can however compare these 3 datasets individually to genomic regions considered to 
be non-fragile (non-FS). We considered non-FSs to be those genomic regions that were not an aCFS
in any of the LUK, BIG or LET datasets nor ever reported to be one of the 230 FSs as reported by 
Mrasek et al. (Mrasek et al. 2010). 
4.4.2 SM density in fragile sites
We divided the genome into non-overlapping 100 kilo-base windows and scored each window as 
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being wholly contained within either a LUK (4940 windows), BIG (2073 windows) or LET (3931 
windows) aCFS or non-FS (8581 windows) if the window was not an aCFS in any of the four 
datasets. Windows that were not defined as either, i.e. reported to harbour infrequently expressed 
FSs by Mrasek et al. (Mrasek et al. 2010), totalling 41% of the genome, were excluded from the 
analysis. The density of SNVs and Indels were then calculated for each window. Figure 4.1 shows 
the median density of SNVs and indels for each dataset. We found that the median SNV density for 
LUK (0.183 SNVs/100kb) and BIG (0.189 SNVs/100kb) were significantly lower, but did not 
change dramatically, from the non-FS controls (0.215 SNVs/100kb) (Mann-Whitney Test, p < 
0.001), whereas the LET SNV density was significantly enriched by 25% (0.268 SNVs/100kb) 
compared to the non-FSs (Mann-Whitney Test, p < 0.001). In no dataset was median indel density 
found to be different from the control (0.0264 indels/100kb).
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Figure 4.1. Boxplots comparing A) median SNV density and B) median indel density for each 
dataset and the non-FS data.
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We examined the LET aCFSs further to try and determine the origin of this SNV enrichment. The 
LET data combines aCFSs from 9 different tissue types so we first investigated if the enrichment 
came from aCFSs identified in any particular tissue. SNV density in aCFSs from 7 of the 9 tissue 
types was significantly enriched from the non-FS control (Mann-Whitney test, p < 0.001) (Figure 
4.2), however many of these differences were modest and the variation around the medians were 
large. The most significant difference (57% enrichment) was in aCFSs from K562 cells. 
Interestingly, the SNV density in lymphocytes, the cells used for the aCFSs in LUK and the cells in 
which most studies have been carried out, were significantly depleted compared to the non-FS 
control.  Only the SNV density in aCFSs from LS174T cells, a colonic adenocarcinoma cell line, 
was not significantly different from the non-FS control. 
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Figure 4.2. Boxplot showing variation in SNV density in aCFSs from each of the 9 tissues types 
from comprising the LET data and the non-FS data (far right).
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4.4.3 SNV density and replication time
It has been shown that replication time correlates strongly with SNV density in somatic tissues (Liu 
et al. 2013; Woo & Li 2012; Schuster-Bockler & Lehner 2012; Koren et al. 2012) and that it is 
important in aCFS etiology (Durkin & Glover 2007; Letessier et al. 2011; Le Tallec et al. 2011). 
Due to the high enrichment of SNVs in aCFSs from the K562 cell line, we examined the 
relationship of SNV density with replication time  for each of the K562 aCFSs. The median 
replication times of each of the 13 K562 aCFSs showed the majority of K562 aCFSs are late 
replicating and that this is highly negatively correlated with the median SNV density (Spearman's 
correlation coefficient r = -0.87, p < 0.0001) (Figure 3).  Interestingly the ~10 mega-bases covering 
FRA16D, the only aCFS found in every tissue type, has a median replication time and SNV density 
very close to that of the genomic average. 
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Figure 4.3. Association between median replication time (circles) and median SNV density 
(crosses) for each of the 13 aCFSs found in K562 cells ranked by SNV density. Vertical lines 
represent one median absolute deviation. Horizontal lines are the non-FS median replication times 
(dashed) and SNV density (solid).
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We thought the density of SNVs in the K562 aCFSs may be simply a consequence of replication 
time. To address this we ran regression models to factor out the influence of replication time on 
SNV density. Using data from all 28,080 windows, combining both aCFS and non-FS windows. We
found that a regression model involving a quadratic term fit the data significantly better than a 
model with only a linear term (ΔAIC = 3016) (Figure 4.4a). However, we also found that a model in
which the K562 aCFS and non-FS had their own relationship between SNV density and replication 
time fit the data better (ΔAIC = 391) (Figure 4.4b), suggesting that the relationship between SNV 
density and replication time differs significantly between the two categories of sites. This difference
seems to be largely down to an enrichment in SNVs in late replicating regions of the genome in 
aCFS.
It is apparent that the greatest enrichment is in late replicating DNA (Figure 4.4b), we find that in 
the latest replicating decile, SNV density is enriched 19% over the effect expected from replication 
time alone (Table 4.1). If this enrichment is a canonical feature of aCFSs then we would expect to 
see this pattern replicated for the other LET tissue types and for LUK and BIG. This is not the case. 
We find considerable variation in ΔAICs when comparing the models for cell type/dataset compared
to the non-FS control, and in the enrichment of SNV density in the latest replicating decile, where 
the ratios of SNV density range from 0.76 – 1.19 (Table 4.1, Appendix 4.1). Fibroblasts are the only
tissue type in which the distribution of SNV density is not significantly different to the non-FS 
control (two-sample t-test) (Table 4.1). Thus we show that variation in SNV density across aCFSs 
can not be explained fully in terms of replication time and that increased SNV density is not a 
canonical feature of aCFSs.
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Figure 4.4. A) The fit of linear (dashed line) and quadratic (solid line) models to mean SNV density
as a product of replication time for all 28,080 100 kilo-base windows. Each point represents one 
window. B) Right - The fit of separate quadratic terms for K562 aCFS (solid line and crosses) and 
non-FS (dashed line and circles) windows.
Table 4.1. Comparison of fitting a quadratic model to variation in SNV densities in aCFS from 
different tissue types and datasets. QM1 AIC = AIC values for a quadratic model for aCFS and 
Non-FS combined, QM2 AIC = AIC values when allowing a separate model for aCFS and Non-FS, 
ΔAIC = QM2 – QM1, aCFS SNV Density = aCFS SNV density in the latest replicating decile of 
windows, Non-FS SNV Density = non-FS SNV density in the latest replicating decile of windows, 
p value = p value obtained from a two-sample t-test comparing the latest replicating aCFS and non-
FS deciles.
QM1 AIC QM2 AIC ΔAIC T-Test t(1) p value
K562FS -24826 -25217 -391 0.50 0.42 1.19 -11.80 <0.0001
BIG -27542 -27568 -27 0.48 0.41 1.15 -6.13 <0.0001
CAL51 -23801 -23804 -3 0.48 0.42 1.15 -4.97 <0.0001
LUK -35644 -35660 -16 0.44 0.41 1.07 -4.10 <0.0001
Fibro -24932 -24939 -8 0.42 0.41 1.01 -0.34 0.738
MRC5 -25184 -25184 0 0.38 0.42 0.91 4.92 <0.0001
LoVo -24495 -24534 -39 0.37 0.42 0.88 6.41 <0.0001
HCT116 -25012 -25128 -116 0.34 0.41 0.81 9.43 <0.0001
MCF10A -24125 -24310 -185 0.34 0.42 0.81 7.86 <0.0001
LS174T -24800 -24928 -128 0.33 0.42 0.80 12.07 <0.0001
Lymph -25916 -26018 -102 0.31 0.41 0.76 14.28 <0.0001
Tissue Type / 
Datset
aCFS SNV 
Density
Non-FS SNV 
Density
Decile 
Enrichment
94
4.5 Discussion
Fragile sites (FS) have been shown to coincide with regions of large-scale genomic instability that 
are susceptible to CNVs and inter-chromosomal rearrangements (Beroukhim et al. 2010; Bignell et 
al. 2010). FS expression and large-scale genomic rearrangements are both linked to replication 
stress. One consequence of replication stress is replication fork breakage followed by attempts to 
restart replication using the homologous recombination machinery (Lambert et al. 2005; Petermann 
et al. 2010). Errors during this process are known to promote non-allelic recombination, one of the 
causes of large-scale rearrangements (Lambert et al. 2005; Lambert et al. 2010; Mizuno et al. 
2009). In several model organisms, once restarted, the replication machinery remains error prone, 
being subject to microhomology mediated template switching, replication slippage and the 
production of elevated levels of SMs (Deem et al. 2011; Sakofsky et al. 2015; Mizuno et al. 2012; 
Iraqui et al. 2012). Our hypothesis was that, if FSs and large-scale genomic rearrangements have an
etiology in replication fork collapse and restart, loci prone to these phenomena would also display 
an increase in the small mutations that are characteristic of the restarted replication. We thus 
investigated if loci associated with aCFSs and large-scale chromosome rearrangements in cancer 
cells also displayed increased SMs. We found no convincing evidence that this is the case, for either
indels or SNVs.  This may highlight a distinction between the biological pathways involved in the 
etiology of small-scale and large-scale mutagenic events and may suggest that, while replication 
fork breakage is a feature of loci prone to fragility, replication fork restart is suppressed at these 
loci.
Defining which regions of the genome are fragile for such an analysis is not straightforward. 
Multiple studies across different tissue types define different regions as being FSs. We simplified 
the matter somewhat by considering only aCFSs for this analysis, however this still left us with data
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from 3 separate studies, which differed in which regions of the genome were considered as aCFSs. 
None of the datasets showed an increase in indel density within aCFSs, although this could be due 
to technical difficulties in detection of indels from next generation sequencing data (Jiang et al. 
2015), and data from two of the studies, BIG and LUK, showed no enrichment of SNVs in aCFSs, 
however initial results from LET suggested that SNVs may be enriched in aCFSs. This was 
interesting as it was the only study to date to investigate the occurrence of aCFSs in tissues other 
than fibroblasts or lymphocytes, covering 9 different cell types in total. Further investigation 
showed that the increase was coming from only a subset of these cell types, with the highest 
enrichment found in K562 cells. When examining the 13 aCFSs found in K562 cells, it was 
apparent that this increase in SNV density was likely due to the late replicating nature of the K562 
aCFSs. This was largely confirmed when regressing SNV density as a function of replication time, 
however we also detected variation in SNV density within aCFSs that was not attributable to 
replication time, although it was most prominent in later replicating regions. Some of this variation 
could be due to our methods of using the average replication times across 5 cell lines; multiple cell 
types have been shown to exhibit different replication time profiles (Morganella et al. 2016) and 
disruption to these profiles throughout differentiation (Lu et al. 2014), however the extreme 
replication time deciles exhibit remarkable conservation and stability across cell types (Morganella 
et al. 2016). Therefore to minimise any potential effect from differing replication time profiles, we 
considered the enrichment of SNVs only in the latest replicating deciles. We found that the K562 
aCFSs were moderately enriched in SNVs, but that this pattern was not common to all tissue types 
or data sets, and therefore does not appear to be a canonical feature of an aCFS. 
We also note that the one ubiquitous aCFS, FRA16D, has an average replication time and SNV 
Density close to to the control. At first glance this would seem to suggest that, contrary to previous 
findings (Durkin & Glover 2007; Ozeri-Galai et al. 2012; Letessier et al. 2011), late replication is 
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not an indicator of fragility. This however highlights the importance of considering scale in an 
analysis. It has been previously demonstrated (Le Tallec et al. 2011) that the effect of late 
replication on FS expression in FRA16D happens over one or two mega-bases that have a paucity 
of replication origins and are replicated by forks traversing long distances. Thus the average 
replication time for an FS region may be inconsequential for FS expression, the fact that it contains 
a mega-base or two of origin poor, late replicating, DNA may be enough to express the FS if the 
replication origins flank this region. 
The majority of previous studies into aCFSs have been carried out in lymphocytes. This analysis 
further supports previous assertions  (Le Tallec et al. 2011) that tissue specificity is important to 
consider when investigating FSs, some aCFS are private to a particular tissue type whereas many 
aCFS are shared among tissues but at varying frequencies (Le Tallec et al. 2011; Le Tallec et al. 
2013). This likely represents the specific biology of individual cell types, demonstrated by the 
differing replication profiles of FRA3B in Fibroblasts and Lymphocytes (Le Tallec et al. 2013).
This analysis uses SMs from a variety of cancer samples, many unrelated to the tissues in which 
these aCFSs were discovered, Therefore the tissue specificity of aCFS expression could be 
obscuring any associations with SMs, however we think this is unlikely to be the case for three 
reasons. First, a large number of aCFS are shared between tissue types, so if there was any 
association between SM and aCFS expression we would expect to see at least a small indication of 
this in the shared aCFS such as FRA3B and FRA16D, however we do not. Second, replication time 
is known to be strongly correlated with SNV density, so by focusing on the latest replication time 
decile, which is largely invariant across tissue types (Morganella et al. 2016), we should minimise 
any tissue specific effects. Third, previous studies have found associations of other features, such as
an overlap of homozygous deletion clusters with aCFSs, when not considering tissue specificity 
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(Bignell et al. 2010). This final point suggests that although tissue specific FS exist, many 
determinants of fragility may not be tissue specific.
Here we have shown that aCFSs are not specifically enriched in either indels or SNVs in cancers 
and that any apparent enrichment of SNVs in aCFS is largely explained by replication time, and 
other, unknown components of moderate effect size. Our analysis thus does not support a 
hypothesis that genetic instability associated with FSs in cancer cells is significantly associated with
attempts to restart broken forks by homologous recombination. We also show that when considering
replication time as a correlate of any phenomenon, resolution is an important aspect. Average 
replication times across multiple mega-bases will capture much of the correlation with SNVs but 
will obscure important features that are pertinent to biological events, such as FS expression at a 
finer scale.
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5. The relationship between divergence, diversity and the rate
of de novo mutation along the human genome.
5.1 Abstract
The rate of divergence between species, and the level of diversity within a species, are expected to 
depend on the rate of mutation. Here we investigate the relationship between divergence, diversity 
and the rate of mutation across the human genome at scales of 1Mb and 100kb using >40,000 de 
novo mutations (DNM). We show that there is significant variation in the rate of DNM across the 
human genome, but the variation is modest. We confirm that the rate of divergence along the human
lineage is correlated to the rate of DNM but that the correlations are weaker than expected. We 
provide evidence that this is due the effect of biased gene conversion (BGC) on the probability that 
a mutation will become fixed. In contrast we find that diversity is almost as strongly correlated to 
the rate of DNM as it can be given the sampling error in the number of DNMs. It therefore seems 
that variation in the mutation rate is the chief determinant of the level of diversity across the human 
genome at the 1Mb and 100kb scales, and this suggests, contrary to previous analyses, that 
recombination does not affect diversity in humans independently of its effect on the mutation rate. 
Finally we show that the correlation between divergence and DNM density declines as increasingly 
divergent species are considered. Our results have important implications for the use of divergence 
and diversity data to study variation in the mutation rate. 
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5.2 Introduction
Until recently, the distribution of germ-line mutations across genome was largely studied using 
patterns of nucleotide substitution between species in putatively neutral sequences - see 
(Hodgkinson & Eyre-Walker 2011 for review of this literature), since under neutrality the rate of 
substitution should be equal to the mutation rate. However, the sequencing of hundreds of 
individuals and their parents has led to the discovery of thousands of de novo mutations (DNMs) in 
humans; it is therefore possible to start analysing the pattern of DNMs themselves rather than 
inferring their patterns from substitutions. Initial analyses have shown that the rate of DNM 
increases with paternal age (Neale et al. 2012; O’Roak et al. 2012; O’Roak et al. 2011; Iossifov et 
al. 2014; Iossifov et al. 2012; Michaelson et al. 2012; Kong et al. 2012; Francioli et al. 2015; Wong
et al. 2016), a result that was inferred by Haldane some 70 years ago (Haldane 1947), that it varies 
across the genome (Michaelson et al. 2012) and that it is correlated to a number of factors, 
including the time of replication (Francioli et al. 2015) the rate of recombination (Francioli et al. 
2015), GC content (Michaelson et al. 2012) and nucleosome occupancy (Michaelson et al. 2012). 
Although, divergence between species has been used to study the pattern of DNM, it has recently 
been shown that the rate of mutation, at a per Mb scale, is not as strongly correlated to the rate of 
nucleotide substitution between species as it could be (Francioli et al. 2015). Instead, the rate of 
substitution appears to be more strongly correlated to the rate of recombination. This might be due 
to one, or a combination, of several factors. First, recombination might affect the probability that a 
mutation becomes fixed by the process of BGC (Duret & Galtier 2009). Second, recombination can 
affect the probability that a mutation will be fixed by natural selection; in regions of high 
recombination advantageous mutations are more likely to be fixed but slightly deleterious mutations
are less likely to be fixed. Third, low recombination leads to high levels of genetic hitch-hiking and 
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background selection, both of which can reduce the time to coalescence in the human-primate 
ancestor, and hence the divergence between species. And fourth, the independent correlation of 
divergence and recombination might simply be due to problems with multiple regression; spurious 
associations can arise if multiple regression is performed on two correlated independent variables 
that are not know without error.
The object of the current study is to examine the large scale distribution of DNMs and to address 
the following questions: (i) to what extent does the mutation rate vary across the human genome at 
a large scale; (ii) does the variation at these scales vary between mutational types; (iii) why does 
divergence between species depend upon the rate of recombination independently of the DNM rate, 
(iv) what is the relationship between human diversity and DNM rate, and (v) does the correlation 
between the rate of DNM and divergence vary between different pairs of mammalian species. 
Because many more DNMs have been published recently we are able to investigate these questions 
at both the 1Mb scale, and a finer scale of 100kb.
5.3 Materials and methods
5.3.1 Alignment comparisions and filtering of alignments.
Three sets of alignments were investigated, all based on human genome build hg19/GRCh37 for 
autosomes only, (i) the University of California Santa Cruz (UCSC) pairwise (PW) alignments 
(Chiaromonte et al. 2002) for human-chimpanzee hg19-panTro4 downloaded from 
http://hgdownload.cse.ucsc.edu/goldenpath/hg19/vsPanTro4/ (ii) UCSC MultiZ (MZ) 46-way 
alignments (Blanchette et al. 2004) downloaded from 
101
http://hgdownload.cse.ucsc.edu/goldenpath/hg19/multiz46way/ and (iii) Ensembl Enredo, Pecan, 
Ortheus (EPO) 6 primate multiple alignment, release 74, (Yates et al. 2016; Paten et al. 
2008) downloaded from ftp://ftp.ensembl.org/pub/release-74/emf/ensembl-
compara/epo_6_primate/. For the PW and MZ alignments, divergence as a function of mean 
alignment length - defined by the number of aligned bases for each alignment row in the alignment 
source files - was calculated per Mb window. This was not possible for the EPO alignments as they 
are constructed using global alignment methods as opposed to the local alignment methods for MZ 
and PW. To investigate the consistency of results produced by all three alignment methods, we 
correlated divergence versus DNM density, iteratively increasing the filter for the minimum number
of interrogable bases per Mb window from 1 to 950,000 in 5000 base-pair steps. Interrogable bases 
were defined as the number of bases defined as A,C,T or G in both species, excluding any gaps "-" 
or unknown nucleotides "N".
5.3.2 Filtering of EPO alignments and construction of main data set.
The filters applied to the alignments have the to potential significantly impact results. From the 
results of the alignment comparison, the EPO alignments provided consistent results over a wide 
range of minimum interrogable bases, remaining relatively unchanged from 200,000 to 900-000 
interrogable bases. We chose a filter of 50% interrogable bases per window as the best compromise 
to retain the maximum number of windows (2,337 out of an initial 2,922) whilst providing 
consistent results. We also removed all windows that did not contain any data for recombinaton rate.
5.3.3 Selection and filtering of DNMs.
From four sources we obtained 43,433 Autosomal DNMs, 547 from Michaelson et al. (Michaelson 
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et al. 2012), 4,931 from Kong et al. (Kong et al. 2012), 11,016 from Francioli et al. (Francioli et al. 
2015) and 26,939 from Wong et al. (Wong et al. 2016). After filtering against interrogable bases in 
the EPO alignments and the filtering methods mentioned in section 5.3.2, this was reduced to 
35,401 DNMs for the human/chimpanzee/orang-utan comparison, 31,185 DNMs for the 
human/orang-utan/macaque comparison and 23,534 DNMs for the human/macaque/marmoset 
comparison.
5.3.4 Selection and filtering of SNPs.
All SNPs from the 1000 genomes project phase 3 (The 1000 Genomes Project Consortium 
2015) were downloaded from hgdownload.cse.ucsc.edu/gbdb/hg19/1000Genomes/phase3/. After 
removing all multi-allelic SNPs and, structural variants and indels we were left with 77,818,368 
autosomal SNPs. After filtering out windows with no recombination rate scores and <50% 
interrogable bases per window we were left with 71,917,321 SNPs.
5.3.5 Genomic features.
Male specific standardised recombination rate data (Kong et al. 2010) was downloded from 
http://www.decode.com/additional/male.rmap which provides recombination rates in 10kb steps. 
For each 100kb and 1Mb window the recombination rate was calculated as the mean of these scores
with a score assigned to the window in which the position of its first base resided. The number of 
scores used to calculate the mean of the window was also recorded and as noted in section 5.3.2 was
used in the filtering process. We downloaded Encode Repli-seq wavelet smoothed signal data 
(Hansen et al. 2010; Thurman et al. 2007), provided in 1kb steps, for the GM12878, HeLa, 
HUVEC, K562, MCF-7 and HepG2 cell lines from the UCSC ftp site 
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ftp://hgdownload.cse.ucsc.edu/goldenPath/hg19/database/. We computed the mean replication time 
for all autosomes for 100kb and 1Mb windows across all 6 cell lines. Replication time were 
assigned to windows based upon their start coordinates. GC content was calculated directly from 
the human genome (hg19/GCRh37) for 100kb and 1Mb windows. Nucleosome occupancy for the 
GM12878 cell line was used (Encode Project Consortium et al. 2012), downloaded from 
/hgdownload.cse.ucsc.edu/goldenPath/hg19/encodeDCC/wgEncodeSydhNsome/. Nucloesome 
occupancy scores are provided at high, but variable resolution, with scores spanning 1 to 27,362 
bases. Mean nucleosome occupancy was calculated per 100kb and 1Mb window, accounting for this
variation. 
5.3.6 Statistical analysis. 
The R stats package, R version 3.3.1, was used for all correlations and regression analyses of 
observed variables (R Core Team 2016). 
For bootstrapping we resampled 2500 windows with replacement to find the slope of the regression 
of normalised divergence and recombination rate, and normalised DNM frequency and 
recombination rate using the lm() function in R. We then minused the slope of the divergence 
from the slope of the DNM frequency to fine the differnece in the slopes. We performed 1000 
replicates and calculated the p-value as the proportion of replicates for which the difference in slope
was negative, or 1 minus the proportion of replicates for mutational types where the slope of 
divergence and recombination rate is greater than that of DNM frequency and recombination rate. 
Simulations to derive expected variables and comparisons to observed variables were done using 
Mathematica (version 7).
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To estimate the mutation rate distribution we use the method of [43]. In brief we assume that the 
mutation rate in each block is αu where u is the average mutation rate per site and α is the rate 
above or below this mean. α is assumed to be gamma distributed. The number of mutations per 
block is assumed to be Poisson distributed with a mean αul where l is the length of the block. This 
means that the number of mutations per block is a negative binomial. We fit the distribution using 
maximum likelihood using the NMaximize function in Mathematica (version 7). 
We investigated the correlation between different types of mutation across blocks by fitting a single 
distribution to both types of mutation; i.e. by finding the distribution which when fitted to both 
distributions of mutations across sites, maximizes the likelihood. We then used this distribution to 
simulate data; we drew a random variate for each block from the distribution assigning this as the 
rate for that block. We then generated two Poisson variates with the appropriate means such that the
total number of DNMs for each type of mutation was expected to be equal the total number of 
DNMs of those types.
5.4 Results
5.4.1 De novo mutations
To investigate large scale patterns of de novo mutations (DNMs) in humans we compiled data from 
four studies which between them had discovered 43,433 DNMs: 26,939 mutations from Wong et al.
(2016), 11016 mutations from Francioli et al. (2016), 4931 mutations from Kong et al. (2012) and 
547 mutations from Michaelson et al. (2012). We divided the mutations into 9 categorines reflecting
the fact that CpG dinucleotides have higher mutation rates than non-CpG sites, and the fact that we 
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cannot differentiate which strand the mutation had occurred on: CpG C->T (a C to T or G to A 
mutation at a CpG site), CpG C->A, CpG C->G and for non-CpG sites C->T, T->C, C->A, T->G, 
C<->G and T<->A mutations. The proportion of mutations in each category in each of the datasets 
are given in table 5.1. 
We find that the pattern of mutation differs significantly between the 4 studies (Chi-square test of 
independence on the number of mutations in each of the 9 categories, p < 0.0001). This appears to 
be largely due to the relative frequency of C->T transitions in both the CpG and non-CpG context. 
In the data from Wong et al. and Michaelson et al. the frequency of C->T transitions at CpG sites is 
~13% whereas it is ~17% in the other two studies, a discrepancy which has been noted before 
between the studies of Michaelson et al. and Kong et al. (Eyre-Walker & Eyre-Walker 2014). For 
non-CpG sites the frequency of C->T transitions is ~24% in all studies except that of Wong et al. in 
which it is 26%. It is not clear whether these patterns reflect differences in the mutation rate 
between different cohorts of individuals, possibly because of age or race, or whether the differences 
are due to methodological problems associated with detecting DNMs. Since the differences are 
relatively small and it is not clear whether one study represents a more representative sample than 
the other, we combined the data.
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Table 5.1. The proportion of mutations in each mutational category in each of the 4 datasets, 
number of mutations in parenthesis.
Mutation type Michaelson Kong Francioli Wong Overall
CpG C-T 0.128 (70) 0.173 (1816) 0.165 (3530) 0.131 (3530) 0.144 (6270)
CpG C-A 0.009 (5) 0.008 (37) 0.007 (79) 0.008 (204 ) 0.007 (325)
CpG C-G 0.009 (5) 0.007 (36) 0.007 (76) 0.006 (160) 0.006 (277)
Non C-T 0.236 (129) 0.237 (1169) 0.246 (2705) 0.264 (7121) 0.256 (11124)
Non T-C 0.28 (153) 0.267 (1319) 0.273 (3011) 0.283 (7636) 0.279 (12119)
Non C-A 0.086 (47) 0.083 (409) 0.084 (930) 0.089 (2399) 0.087 (3785)
Non T-G 0.073 (40) 0.073 (358) 0.073 (808) 0.071 (1920) 0.072 (3126)
Non C-G 0.097 (53) 0.085 (417) 0.081 (896) 0.088 (2372) 0.086 (3738)
Non T-A 0.082 (45) 0.067 (332) 0.063 (695) 0.059 (1579) 0.072 (2669)
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5.4.2 Distribution of rates
In thinking about large-scale variation in the mutation rate it is helpful to quantify the level of 
variation. This is not entirely straightforward since we have on average only 15 DNMs per Mb and 
hence a large level of sampling error. To overcome this problem we modelled the underlying 
variation in the mutation rate as a gamma distribution allowing mutations within each block to be 
Poisson distributed (i.e. the error variance was Poisson distributed), estimating the distribution 
using maximum likelihood (see chapter 2 for details of the method (Smith et al. 2016)). We fit a 
gamma distribution to the numbers of mutations dividing the genome into either 100kb or 1Mb 
windows. We do not consider scales below these because we have too little data - at 100kb we only 
have ~1.5 DNMs per region. 
For the 1Mb data we find significant variation (i.e. the lower 95% confidence interval is not zero) 
when all mutations are considered together, however the level of variation is quite modest. We 
estimate the coefficient of variation (the standard deviation divided by the mean) of the distribution 
to be between 0.13 and 0.20 for most categories of mutation (Table 5.2). A gamma distribution with 
a coefficient of variation of 0.18 is a distribution in which only 10% of regions have a rate of 
mutation that is either 30% faster or 30% slower than the mean. The coefficient of variation is about
twice as great at the 100kb level, but again this represents rather limited variation in the mutation 
rate; roughly 10% of regions have mutation rates that are either 60% slower or faster than the mean.
We also find significant variation for CpG transitions and non-CpG transitions and transversions 
(Table 5.2). However, we do not find significant variation for either CpG transversions, or when we 
split the data into individual mutational types; this is probably because we have too little data. 
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Table 5.2. The coefficient of variation for a gamma distribution fitted to the density of DNMs, and 
the 95% confidence intervals of the coefficient of variation.
Mutation type 100kb 1Mb
All 0.40 (0.38, 0.41) 0.18 (0.17, 0.20)
CpG 0.35 (0.23, 0.45) 0.20 (0.13, 0.26)
nonCpG 0.24 (0.22, 0.27) 0.14 (0.12, 0.16)
CpG transitions 0.36 (0.22, 0.46) 0.19 (0.11, 0.26)
CpG transversions 0 (0, 0.95) 0.39 (0, 0.67)
nonCpG transitions 0.20 (0.15, 0.25) 0.13 (0.091, 0.15)
nonCpG transversions 0.29 (0.21, 0.35) 0.18 (0.14, 0.22)
109
Given that there is variation in the rate of all mutational types, for which we have enough data, it is 
of interest to investigate whether the amount of variation differs between the mutational types. To 
investigate this we ran a series of likelihood ratio tests in which we fit separate and common 
distributions to the different mutational types. We found no significant differences in the amount of 
variation for CpG and non-CpG mutations or CpG transitions and CpG transversions (Table 5.3). 
However, we found evidence that there was significantly more variation for non-CpG transversions 
than transitions (p<0.05) (Table 5.3). Never-the-less, although significant, the differences in terms 
of the coefficient of variation are quite modest (Table 5.2).
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Table 5.3. Likelihood values for fitting combined and separate distributions to categories of 
mutations. Each pair of lines represents a likelihood ratio tests; bold figures denote a significant 
result.
Model No of parameters Log likelihood
100 kb
Combined distribution for CpG and non-CpG 3 -54408.9
Separate distributions for CpG and non-CpG 4 -54407.3
Combined distribution for CpG transitions and transversions 3 -17634.5
Separate distributions for CpG transitions and transversions 4 -17634.44
Combined distribution for non-CpG transitions and transversions 3 -55347.3
Separate distributions for non-CpG transitions and transversions 4 -55345.5
1 Mb
Combined distribution for CpG and non-CpG 3 -12022.2
Separate distributions for CpG and non-CpG 4 -12020.63
Combined distribution for CpG transitions and transversions 3 -6046.3
Separate distributions for CpG transitions and transversions 4 -6045.92
Combined distribution for non-CpG transitions and transversions 3 -12332.9
Separate distributions for non-CpG transitions and transversions 4 -12330.03
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5.4.3 Correlations between mutational types
Given that there is variation in the mutation rate at the 1Mb and 100kb levels and that this variation 
is quite similar for different mutational types, it would seem likely that the rate of mutation for the 
different mutational types are correlated. We find that this is indeed the case. At the 1Mb scale we 
find that the rate of CpG mutations is significantly correlated the rate of non-CpG mutations (r = 
0.086, p < 0.001 by randomisation), and the rate of non-CpG transitions is correlated to the rate of 
non-CpG transversions (r = 0.075, p < 0.001). In both cases these correlations are about as strong as
you would expect given the high level of sampling error; i.e. if we simulate data using a gamma 
distribution fit to both mutational categories, we find the mean correlation from 100 simulations are 
0.080 and 0.083 respectively. In contrast we observe no significant correlation between the rates of 
CpG transitions and CpG transversions (r = 0.018, p = 0.17) but this appears to be due to the 
scarcity of CpG transversions, because the simulated data also show similarly low correlations 
(mean r = 0.019 from 100 simulations).
The pattern at the 100kb scale is slightly different. The rates of CpG and non-CpG mutations are 
significantly correlated to each other (r = 0.013, p = 0.02), as are the rates of non-CpG transitions 
and non-CpG transversions (r = 0.036, p < 0.001). However, whereas the correlation between non-
CpG transitions and non-CpG tranversions is similar to the expected value (mean simulated r 
=0.030) the correlation between CpG and non-CpGs is considerably smaller than the expected value
(mean simulated r = 0.031) and less than 2% of simulated datasets have such a low correlation at 
the 100kb scale.  The rate of CpG transversions is not correlated to the rate of non-CpG 
transversions (r = 0.0084, p = 0.088), which is consistent with simulated data (mean r = 0.0069), 
again reflecting the paucity of CpG transversions.
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In summary there are significant correlations between the rates of CpG and non-CpG mutation, and 
non-CpG transitions and transversions, at both the Mb and 100kb scales, and these correlations are 
as strong as one would expect given the sampling error; this is with the exception of the correlation 
between CpG and non-CpG mutations at the 100kb scale, which is smaller than expected. There is 
no significant correlation between the rates of CpG transitions and CpG transversions, but this is as 
expected given the number of CpG transversions.
5.4.4 Correlations with genomic variables
To try and understand why there is large scale variation in the mutation rate, we compiled a number 
of genomic variables which have previously been shown to correlate to the rate of germline or 
somatic DNM, or divergence between species: recombination rates, GC content, replication time 
and nucleosome occupancy. All the variables are significantly correlated to the rate of DNM except 
replication time in the 1Mb analysis (Table 5.4). However, the lack of a correlation with replication 
time is deceptive, because if we run a multiple regression we find that all factors are significant 
including replication time. We also find that for almost all the individual mutational types the rate of
DNM is negatively correlated to replication time (early replicating DNA has a lower mutation rate)
(see appendix 5.1). A comparison of the standardised slopes suggests that nucleosome occupancy is 
the factor most strongly associated with the mutation rate followed by replication time and 
recombination rate. 
113
Table 5.4. The correlation coefficients from regressing DNM rate against individual features and 
the standardized slopes from including all significant features in a multiple regression. Note that a 
negative slope for replication time indicates that the mutation rate is higher for later replicating 
regions. 
100kb 100kb 1Mb 1Mb
Factor Correlation Slope Correlation Slope
GC content 0.053*** NS 0.097*** 0.16
Recombination rate 0.071*** 0.046 0.20*** 0.11
Replication time 0.014* -0.09 0.017 -0.22
Nucleosome occupancy 0.077*** 0.12 0.15*** 0.44
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5.4.5 Correlation with divergence
The rate of divergence between species is expected to depend, at least in part, on the rate of 
mutation; patterns of substitution between species have commonly been used to infer patterns of 
mutation (Williams & Hurst 2000; Martin J. Lercher & Hurst 2002; Smith & Lercher 2002; M J 
Lercher & Hurst 2002; Hellmann et al. 2003; Tyekucheva et al. 2008; Duret & Arndt 2008; 
Stamatoyannopoulos et al. 2009; Don et al. 2013; Prendergast et al. 2007; Hodgkinson & Eyre-
Walker 2011). However it is not known to what extent the variation in DNM density represents 
divergence. To investigate this we calculated the rate of divergence between humans and 
chimpanzees and correlated this to the denisity of DNMs in non-overlapping 1Mb windows. There 
are at least three different sets of human-chimpanzee alignments available, Ensembl EPO 
alignments (EPO), UCSC Pairwise (PW) and  MultiZ 46-Way (MZ) alignments, and we find that 
the correlation between human DNM density and divergence depends upon the alignments used and
the filtering applied to the windows (Figure 5.1). The correlation is significantly negative if we 
include all windows for the PW and MZ alignments, becoming more positive as we restrict the 
analysis to windows with more interrogable bases. In contrast the correlations are always positive 
when using the EPO alignments, and the strength of this correlation does not change once we get 
above 200,000 interrogable bases per 1Mb. Further analysis suggests there are some problems with 
the PW and MZ alignments; divergence per Mb window is inversely correlated to mean alignment 
length (r = -0.31, p < 0.0001) for the PW alignments and positively correlated (r = 0.57, p < 0.0001)
for the MZ alignments (Appendix 5.2). The EPO alignments use a global alignment method (Paten 
et al. 2009), as opposed to local methods used for PW and MZ and as such can not exhibit such a 
bias. We consider these to be of the highest quality. Therefore we use the EPO alignments for the 
rest of this analysis. Figure 5.2 shows the correlation between DNM frequency and divergence for 
the EPO alignments.
115
Figure 5.1. Correlation Coeffiecients of DNM density versus divergence as a function of the 
minimum number of interrogable sites per Mb window in steps of 5000 bases. The result for 3 
alignment methods are shown; PW (blue circles), MZ (green circles) and EPO (black circles). 
Crosses denote the number of windows remaining when each filter is applied.
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Figure 5.2. Graph showing the correlation of DNM frequency and divergence for the EPO 
alignments at 1Mb, filtered for windows only containing >500,000 interrogable sites (2,337 1Mb 
windows) with a correlation coefficient of 0.24. DNM frequency and divergence has been scaled, 
the axes represent units of standard deviation. 
117
The EPO alignments allow us to consider lineage specific changes using parsimony to reconstruct 
ancestral states. As expected the divergence along the human lineage is correlated to the rate of 
DNM (0.24 at the 1Mb scale, 0.064 at the 100kb scale, p < 0.0001). However, the correlation 
between the rate of DNMs and divergence is not expected to be perfect even if variation in the 
mutation rate is the only factor affecting the rate of substitution between species; this is because we 
have relatively few DNMs and hence our estimate of the density of DNMs is subject to a large 
amount of sampling error. To investigate how strong the correlation could be, we follow the 
procedure suggested by Francioli et al. (2015); we assume that variation in the mutation rate is the 
only factor affecting the substitution rate between species and that we know the substitution rate 
without error (this is an approximation, but the sampling error associated with the substitution rate 
is small relative to the sampling error associated with DNM density). We then simulate the observed
DNMs for each window using the rate of substitution for each window as the mean rate for the 
poisson process, and then consider the correlation between these simulated DNMs and the observed
substitution rates. We repeated this procedure 10,000 times to generate a distribution of expected 
correlations. Doing this we find that the correlation between divergence and DNM density could be 
0.50 at the 1Mb level and 0.24 at 100kb level, considerably greater than the observed values of 0.24
and 0.064 respectively (Table 5.5). In none of the simulations was the simulated correlation lower 
than 0.44 for 1Mb and or 0.21 for 100kb. Similar patterns hold for almost all mutational types 
(Table 5.5).
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Table 5.5. The observed and expected correlations between the density of DNMs and substitutions 
at the 100kb and 1Mb scales; the expected correlation is the mean correlation from 10,000 
simulations assuming that all the variation in the substitution rate is due to variation in the mutation 
rate (and assuming the pattern of mutation has not changed along the human lineage). We are not 
able to simulate data for CpG transversions due to the fact that some regions have no substitutions 
of this type.
100kb 100kb 1Mb 1Mb
Mutation Obs. correlation Exp. correlation Obs. correlation Exp. correlation
All 0.064 0.24 0.24 0.5
CpG C-T 0.055 0.11 0.2 0.21
CpG C-A 0.021 NA 0.053 0.086
CpG C-G 0.011 NA 0.033 0.085
non C-T 0.016 0.14 0.063 0.29
non C-A 0.047 0.12 0.16 0.27
non T-C 0.015 0.14 0.08 0.32
non T-G 0.0099 0.096 0.04 0.21
non C-G 0.059 0.11 0.23 0.26
non T-A 0.013 0.091 0.094 0.18
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5.4.6 The effect of recombination
There are several potential explanations for why the correlation is weaker than it could be; the 
pattern of mutation might have changed, or there might be other factors that affect divergence. 
Francioli et al. (2015) showed that including recombination in the regression model significantly 
improved the correlation between divergence and DNM density; a result we confirm here; the 
square root of coefficient of determination when recombination is included in a regression of 
divergence versus DNM density increases from 0.24 to 0.43, and from 0.064 to 0.22 for the 1Mb 
and 100kb datasets respectively. As detailed in the introduction there are at least four explanations 
for why including recombination in the regression might improve the correlation: (i) BGC can 
affect the probability of a mutation reaching fixation, countering S>W mutations and driving the 
fixation of W>S mutations, thus substitutions in regions of high recombination may reflect the 
processes of both BGC and de novo mutation. (ii) Recombination can also affect the probability that
a mutation will be fixed by natural selection; in regions of high recombination deleterious mutations
are less likely to be fixed, whereas advantageous mutations are more likely, and so the pattern of 
substitution may reflect both selection as influenced by recombination and de novo mutation. (iii) 
Recombination can affect the depth of the genealogy in the human-chimpanzee ancestor; regions of 
low recombination can increase the effects of hitch-hiking and background selection, resulting in a 
lower effective population size and thus less diversity in the ancestor. As ancestral polymorphisms 
segregate into the human and chimpanzee branches, regions of low recombination will therefore 
have a fewer ancestral polymorphisms contributing to divergence between the two species than 
regions of higher recombination. (iv) Problems with regressing against correlated variables that are 
subject to sampling error. For example, let us imagine that factor X (de novo mutation) affects 
diversity directly whereas factor Y (recombination rate) does not; however, X and Y are mildly 
correlated - This could be the case if recombination is mutagenic but does not exhibit BGC. If we 
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can measure X and Y without error then a multiple regression should show that diversity is 
correlated to X but not Y. However, if we cannot measure X without error then we may find that the
rate of diversity correlates to both X and Y. 
We can potentially differentiate between these four explanations by comparing the slope of the 
regression between the rate of substitution and recombination rate, and the rate DNM and 
recombination rate. If recombination affects the substitution rate independent of its effects on DNM 
mutations because of BGC, then we expect the slope associated with the substitution rate to be 
greater for AT->GC, smaller for GC->AT, and unaffected for G<->C and A<->T changes. If 
selection is the cause then we expect all the slopes associated with substitutions to be less than those
associated with DNMs. The reason is as follows; if a proportion of mutations are slightly 
deleterious then those will have a greater chance of being fixed in regions of low recombination 
than high recombination. If the effect of recombination is due to variation in the coalescence time in
the human-chimp ancestor, then we expect all the slopes associated with substitution to be greater 
than those associated with DNMs; this because the average time to coalescence is expected to be 
shorter in regions of low recombination than in regions of high recombination. Finally, if the effect 
is due to problems with multiple regression then we might expect all the slopes to become 
shallower. Since the DNM density and divergences are on different scales we divided each by their 
means to normalise them and hence make the slopes comparable.
As Francioli et al. (2015) noted, the overall rate of DNM is positively correlated to the rate of 
recombination, suggesting that recombination might be mutagenic (Tables 5.4, 5.6). The average 
mutation rate in the decile with the highest recombination rate is approximately 20% higher than the
mutation rate in the lowest decile (Figure 5.3). We are able to show in addition that the rate of DNM
is correlated to the recombination rate at both the 1Mb and 100kb scales and for almost all 
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mutational types; the exceptions are non-CpG T->G and T<->A at both scales, and non-CpG C->A 
at the 1Mb scale (Table 5.6).
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Table 5.6. Slope of the regression of the divergence along the human lineage, since the split with 
chimpanzees, and recombination rate, and the slope of the regression of the DNM rate and 
recombination rate for 100kb and 1Mb windows, and the result of testing whether the slopes are 
significantly different, using bootstrapping. * p<0.05, ** p<0.01, *** p<0.001.
Figure 5.3. Normalised DNM density for each recombination rate decile from lowest (1) to highest 
(10). Vertical lines represent the standard error.
100kb 1Mb
DNM v RR Div v RR Difference test p-value DNM v RR Div v RR Difference test p-value
Total 0.042*** 0.028*** 0.13 0.069*** 0.066*** 0.38
CpG C>T 0.039** -0.005*** 0.09 0.043* -0.009 0.001
C>T 0.037*** 0.006*** 0.09 0.063*** 0.016*** <0.001
C>A 0.042** -0.004** 0.11 0.036 -0.014* 0.001
T>A 0.022 0.010*** 0.4 0.041 0.026*** 0.28
T>C 0.019** 0.042*** 0.15 0.035** 0.096*** <0.001
T>G 0.007 0.044*** 0.18 0.013 0.106*** <0.001
C>G 0.061*** 0.027*** 0.22 0.090*** 0.076* 0.26
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In terms of our test of why the substitution rate depends upon the recombination rate independent of
its effects on the mutation rate, we find that the slopes are less positive, and sometimes even 
negative, for all GC->AT changes and more positive for AT->GC changes (we do not consider CpG 
transversions because there are too few DNMs) (Table 5.6). These differences in the slopes, as 
determined by bootstrapping, are significant at the 1Mb scale but non-significant at the 100kb scale.
We find no significant difference in the slopes associated with A<->T and G<->C at either scale. 
These results are highly consistent with BGC affecting the rate of substitution between species.
5.4.7 Other species
Divergence between species, usually humans and macaques, is often used to control for mutation 
rate variation in various analyses (Gossmann et al. 2011; Burgess & Yang 2008; McVicker et al. 
2009). But how does the correlation between divergence and the DNM rate in humans change as the
species being compared get further apart? To investigate this we compiled data from a variety of 
primate species – human/chimpanzee/orang-utan (HCO) considering the divergence along the 
human and chimp lineages, human/orang-utan/macaque (HOM) considering the divergence along 
the human and orang-utan lineages, and human/macaque/marmoset (HMM) considering the 
divergence along the human and macaque lineages. This yields two series of divergences of 
increasing evolutionary divergence: the human lineage from HCO, HOM and HMM, and chimp 
from HCO, orang-utan from HOM and macaque from HMM. All divergences were normalised by 
dividing by their mean. For both series we see a clear tendency for the slope of the regression 
between divergence and DNM rate to decrease as a function of evolutionary divergence at both the 
100kb and 1Mb scales (Figure 5.4). If we calculate the correlation coefficient between the slope and
the evolutionary stratum, assigning 1, 2 and 3 to the strata (e.g. 1 for chimp, 2 for orangutan and 3 
for macaque), we find that the correlations are negative for all mutational types, for both sets of 
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evolutionary divergence and scales (binomial test of positive versus negative for both 100kb and 
1Mb p < 0.01) (Figure 5.4). 
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Figure 5.4. The slope of the linear regression between divergence and DNM rate for 1Mb (top 
panels; A and B) and 100kb (bottom panels; C and D). HCO is the divergence since humans split 
from chimpanzee, from a comparison of human, chimpanzees and orang-utans; HOM is the human 
divergence since humans split from orang-utans, using human, orang-utan and macaque; HMM is 
the human divergence since humans split from macaques using human, macaque and marmoset). 
The left panels; A and C are for substitutions specific to the human lineage, the right panels; B and 
D are for substitutions specific to the chimpanzee, orang-utan and macaque lineages.
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5.4.8 Correlation with diversity
Just as we expect there to be correlation between divergence and DNM rate, so we might expect 
there to be correlation between DNA sequence diversity within the human species and the rate of 
DNM. To investigate this we compiled the number of SNPs in 1Mb and 100kb blocks from the 
1000 genome project (The 1000 Genomes Project Consortium 2015). There is a positive correlation
between SNP density and DNM rate at both the 1Mb (r = 0.36, p<0.001) and 100kb scales (r = 0.13,
p<0.001).
Using a similar strategy to that used in the analysis of divergence we calculated the correlation we 
would expect if all the variation in diversity was due to variation in the mutation rate by assuming 
that the level of diversity was known without error, and hence was a perfect measure of the 
mutation rate (we have on average 31,000 SNPs per 1Mb, so there is little sampling error associated
with the SNPs). We then simulated the observed number of DNMs according to these inferred 
mutation rates. The expected correlations are 0.41 at the 1Mb and 0.17 at the 100kb scales, 
significantly (p<0.01 in both cases), but only slightly greater than the observed correlations. This is 
consistent with the role of BGC affecting the fate of new mutations, because just as with selection, 
BGC is expected to affect the probability of fixation more than the probability of contributing to 
diversity. To illustrate this we can use the following reasoning; for S>W mutations in areas of high 
recombination, BGC will work against the derived W allele to fix the ancestral S allele. The derived
W allele may persist for some time in the population but will ultimately be removed by BGC, thus 
BGC has a greater effect on divergence than diversity, effectively reducing divergence for S>W 
substitutions in areas of high recombination. For W>S mutations, in areas of high recombination 
BGC favours the derived allele, S, effectively pushing it quickly through the population to fixation, 
again having a greater effect on divergence over diversity, here increasing divergence for W>S 
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substitutions. In both cases, whether the result is an increase or decrease divergence for highly 
recombining areas, we can see that divergence is more sensitive to the force of BGC than diversity.
5.5 Discussion
We have considered the large-scale distribution of DNMs along the human genome and the 
relationship between the rate of DNM, divergence between species, and diversity within a species. 
We find that there is significant variation in the mutation rate at both the 1Mb and 100kb scales (we 
cannot investigate smaller scales due to a lack of DNMs). However, the variation in the mutation 
rate is quite modest; at the 1Mb scale 90% of regions have a mutation rate that is within ± 30% of 
the mean, at the 100kb scale this increases to ± 60% of the mean. It seems likely that there will be 
more variation at smaller scales.
Although we do not have enough DNM data to consider each mutational type individually it is 
evident that the rate of CpG and non-CpG mutations varies across the genome as does the rate non-
CpG transitions and transversions at both the 1Mb and 100kb scales; we do not have enough data to
determine what is happening with CpG transversions. The rate of mutation of the different 
mutational types are about as strongly correlated to each other as they could be suggesting that they 
are influenced by similar factors. That is, the correlation we observe between different mutational 
types, say CpG and non-CpG mutations, is very close to the correlation we get when simulating 
DNMs for CpG and non-CpG mutations from the same distribution - see section 5.3.6 for methods.
We confirm that replication time, recombination rate and GC content are all independently 
correlated to the rate of DNM, however the strongest effect we find comes from nucleosome 
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occupancy. Although, nucleosome occupancy has previously been investigated, no significant 
effects were detected at these scales (Michaelson et al. 2012). However, this study only considered 
a small number of DNMs and at smaller scales of 100bp it did infer a significant effect of 
nucleosome occupancy. As nucleosome occupancy is intimately related to the secondary DNA 
structures, this may support a role for chromatin architecture in the determination of mutation rates 
at large scales, as has previously been postulated (Makova & Hardison 2015; Don et al. 2013).
As expected the rate of divergence between species is correlated to the rate of DNM, however, as 
Francioli et al. (2015) showed the correlation is worse than it would be if variation in the mutation 
rate was the only factor affecting divergence. They showed that although the rate of DNM is 
correlated to the rate of recombination, as might be expected if recombination is mutagenic, that 
divergence is also correlated to the rate of recombination independently of this effect, as you might 
expect from the effect of BGC. We have shown that the reason recombination affects divergence, 
independent of its effect on mutation, is indeed likely to be due to effect of BGC, since the slope of 
the relationship between divergence and recombination rate is smaller than the slope for DNM rate 
and recombination for GC->AT changes, but greater for AT->GC changes; A<->T and G<->C 
changes are unaffected. 
We also show that the relationship between divergence and DNM rate gets weaker (the slopes get 
shallower) as more and more divergent species are considered. This might be due to two factors. 
First we might expect the mutation rate of a region to evolve through time eroding the relationship 
between divergence and the current mutation rate. Second, the relationship might get weaker 
because we are underestimating the divergence as species get more divergent. This might tend to 
affect more divergent blocks the most. However, we see no obvious evidence of this; the mutation 
that should be most affected is CpG transitions and the decay in the slope (between divergence and 
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DNM rate) is no faster than for other mutational types (Figure 5.4).
Divergence between species has often been used to control for mutation rate variation in humans - 
see (Gossmann et al. 2011; Burgess & Yang 2008; McVicker et al. 2009). This is clearly not 
satisfactory given that divergence is more strongly correlated to the rate of recombination than the 
rate of DNM, and the relationship between divergence and the rate of DNMs decreases as 
evolutionary divergence increases. In the coming years it is likely that many more thousands of 
DNMs will be discovered and a high-resolution map of the rate of mutation across the human 
genome will be produced. In the meantime however it seems that diversity within humans is a better
proxy for mutation rate variation than divergence, since the correlation between diversity and 
divergence is about as good as it can be. Never-the-less two questions remain unresolved. Over 
what scale does the mutation rate in humans vary? And if its at a smaller scale than 100kb, does 
diversity still mirror this variation accurately?
It has been known for sometime that diversity across the human genome is correlated to the rate of 
recombination (Martin J. Lercher & Hurst 2002; Hellmann et al. 2003; Hellmann et al. 2005) and 
there has been much debate about whether this is due to mutagenic effects of recombination or the 
effect of recombination on processes such as genetic hitch-hiking and background selection. 
Divergence between humans and other primates is correlated to the rate of recombination, which 
was initially interpreted as being due to a mutagenic effect of recombination, but subsequently it has
been interpreted as evidence of BGC. Both of these hypotheses appear to be correct – as we have 
shown here and as Francioli et al. (2015) show, the rate of DNM is correlated to the rate of 
recombination, but the recombination rate also affects which mutations become fixed through BGC.
However, it has also been shown that there is a correlation between diversity and recombination 
even when divergence is controlled for (Hellmann et al. 2005) and this has led to the suggestion that
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diversity is also affected by linked selection in humans. If we run a multiple regression of SNP 
density against the rate of DNM and recombination we find that both factors are significant at both 
the 1Mb and 100kb scales. However, the independent effect of recombination could simply be due 
to the fact that both the DNM rate and recombination rate are measured with error. An illustration of
this probleem is given in section 5.4.6. This demonstrates that recombination could appear to be 
independently correlated to SNP density, even though its only effect is on the mutation rate. Our 
analysis of the correlation between SNP density and the rate of DNMs would suggest that there is 
little or no independent effect of recombination impacting diversity within humans because the 
correlation is almost as strong as it could be.
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6. Discussion and Conclusions.
6.1 The importance of mutations
The rate of mutation is important in the contexts of both evolution and disease. In evolutionary 
studies, it is central to the concept of a molecular clock and important for phylogenetic dating, from 
which much of our understanding of our evolutionary history is derived. Deleterious mutations are 
the cause of many diseases, including cancers, so it follows that the rate of mutation at a disease 
causing locus will affect the prevalence of the disease. Thus variation in the mutation rate along the 
human genome, if not properly understood and accounted for, has the potential to confound 
evolutionary studies, produce spurious driver candidates in cancer studies, and hinder the  
diagnostics aimed at understanding the etiologies of genetic diseases. 
6.2 The key contributions of this thesis
In this thesis I considered mutation rate variation in both the germ-line and somatic tissues, at 
varying scales. In the germ-line, the major advance of this thesis over previous works is use of 
direct methods to analyse the magnitude, scale and determinants of mutation rate variation. This has
enabled us to tease apart the evolutionary and mutational forces, whilst directly quantifying the 
variation in the human mutation rate at different scales; at large scales the variation appears to be 
quite modest, however at the single nucleotide scale there is potentially huge cryptic variation in the
mutation rate. I have also sought to extend this work into somatic tissues, however due to the 
quality of data and heterogeneity of samples and cell types, the primary findings lean towards 
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highlighting areas of improvement for NGS pipelines, and the development of methods with which 
future studies could provide more insight. With these methods and the ever increasing flow of 
somatic SNVs, coupled with the continual improvements in NGS technology, it should soon be 
possible to provide accurate answers to the questions posed of somatic mutation rate variation in 
this thesis.
6.3  Direct measurements of human mutation rate variation
In chapter 2, I use DNMs from disease genes to quantify the variation in the mutation rate at the 
single nucleotide level. In doing so I present the first direct estimate of cryptic variation in the 
germ-line, a phenomenon only previously inferred from comparative methods (Johnson & 
Hellmann 2011; Hodgkinson et al. 2009). For all mutations excluding the hyper-mutable CpG 
transitions, the best estimate indicates that cryptic variation in the mutation rate varies hundreds to 
thousands of fold between sites. This far exceeds the estimates from previous comparative studies 
by at least one order of magnitude (Johnson & Hellmann 2011; Hodgkinson & Eyre-Walker 2011). 
By contrast, the hyper-mutable CpG transitions exhibit very little variation in their mutation rate. 
However their overall rate of mutation relative to non-CpG transversions appear to be much higher 
in these disease genes (90 - 640 fold), when compared to the whole genome (19 to 28 fold). We 
must be cautious when interpreting these results. Although mutation rate variation is the most likely 
origin of the heterogeneity, and every effort has been made to remove other causes, such as variable 
penetrance, ascertainment bias or alternative splicing, we can not entirely exclude these 
possibilities. In addition, the sample size is relatively small, and so only allows the analysis of four 
mutation types; CpG, non-CpG, transition and transversion, limiting the power of the analysis. 
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In chapter 5, I use ~43,000 DNMs from whole genome sequenced pedigrees, which enabled the the 
direct quantification of mutation rate variation at larger scales. I showed that the variations in 
mutation rate at the 1Mb and 100kb scales are modest, with the ratio of the rates of the first and last 
deciles being 2 and 3 respectively. These rates are significantly below those found at the single 
nucleotide level, in terms of both cryptic variation described in chapter 2 and in context dependent 
variation from other direct studies (Kong et al. 2012; Michaelson et al. 2012). It demonstrates the 
need to consider different determinants of variation at different scales; it is clear that most of the 
variation that does exist is at the fine scale, and although there is variation at large scales, it can not 
all be explained in terms of fine scale variation. It is hoped that in the near future enough DNMs 
will be available to extend this analysis to the 10Kb scale, where I would predict we would find 
greater than the 3-fold variation that we see at the 100kb scale.
6.4  Comparative versus direct methods
Much of our inferences about mutation rates has come from investigating patterns of divergence; 
the assumption usually being that only a small fraction of the genome is under selection, thus 
patterns in the "neutral" parts of the genome should broadly represent the patterns of mutation and 
maybe other non-selective evolutionary processes. The recent release of ~43,000 DNMs has 
allowed, for the first time with sufficient power, a direct comparison of the patterns of DNM 
density, divergence and diversity. Surprisingly, in chapter 5, I show that the pattern of divergence 
does not actually represent the pattern of mutation very well. The variation in DNM density has a 
correlation coefficient of only half of what we would expect with the power we have, in agreement 
with previous work (Francioli et al. 2015).  My analysis suggests that this is due to the process of 
BGC. In contrast, variation in the rate of mutation seems to explain almost all the variation there is 
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in diversity, at least at the scales I have considered. Interestingly diversity and divergence are highly
similar in their patterns of substitution; variation in diversity can explain 62% of the variance in 
divergence, suggesting the processes shaping our genomes beyond that of mutation work on small 
evolutionary timescales, within a species. Furthermore, when regressing substitution density 
between humans and other primates of increasing evolutionary distance against DNM density, we 
note that although the relationship weakens, it remains relatively strong even with species as 
diverged as marmoset. This suggests that although these evolutionary processes may act upon our 
genomes over short timescales, their footprints remain apparent for a long time.
Much attention has been given to genomic features that are thought to influence mutation rates, 
such as GC content (Hellmann et al. 2005; Wolfe et al. 1989; Tyekucheva et al. 2008; Don et al. 
2013; Chen et al. 2010) and replication time (Chen et al. 2010; Pink & Hurst 2010; 
Stamatoyannopoulos et al. 2009; Don et al. 2013) and those involved in chromatin architecture  
(Polak et al. 2015; Makova & Hardison 2015). Replication time is one of the strongest correlates in 
both comparative genomics and somatic studies and the evidence presented in chapter 5, suggests 
that it is fairly strongly associated with DNM density for most mutational types. However, the 
association appears to be stronger with divergence than DNM density. Out of the features I 
investigated, nucleosome occupancy, which is linked to chromatin organisation (Makova & 
Hardison 2015; Don et al. 2013), appears to be have the strongest association to DNM density. This 
has previously only been shown to be to be correlated at much smaller scales (Michaelson et al. 
2012), and so chapter 5 provides the first direct evidence that determinants of chromatin 
architecture at large scales influence mutation rate.
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6.5 Somatic mutation rate variation
When more than 3 million SNVs from over 500 cancers containing many recurrently hit sites were 
publicly released (Alexandrov et al. 2013), it presented a great opportunity to apply the methods 
from chapter 2 to somatic SNVs, to produce the first quantification of cryptic variation in somatic 
tissues. The ~1000 mutations per Mb allowed enough power to comprehensively control for the 
effect of neighbouring nucleotides on the mutation rate. However, when many of the recurrently hit 
sites appeared to be artifactual, it prompted an extension to the method, to try and quantify the level 
of error in the data. I concluded that 2-4% of SNVs were the product of error. With the rate of error 
this high, it was not possible to accurately quantify the level of cryptic variation. However, this 
finding was important in highlighting the highly site specific, yet cryptic error emanating from NGS
pipelines. It demonstrates that recurrence of mutation, often used to detect drivers of cancers or 
disease causing variants, can not be taken alone as evidence of causality. Other considerations, such 
as the mappability of a region, or validation with other methods should also be sought.  The 
accuracy of NGS technology is also continually improving, so as cohorts of whole genome 
sequenced cancers increase in size - such as the recently released 560 breast cancers (Morganella et 
al. 2016) - improving the homogeneity of sample processing and NGS work-flows, it is foreseeable 
that the aim of accurately quantifying the cryptic variation in somatic tissues will soon be possible.
Although chapter 3 estimated 2-4% of SNVs were errors, these were highly site specific, and thus 
only significantly affect the results of analyses at the single nucleotide scale. Therefore, in chapter 
4, using the same data chapter 3, the aim was to investigate the relationship of SNVs with fragile 
sites (FS), a phenomenon associated with larger scales. This had not been attempted before, despite 
both SNVs and FSs being linked to genomic instability and potentially sharing a common biology 
in their mechanism of formation. To our surprise we could find no strong evidence linking the 
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distribution of SNVs to FSs. However, there were many challenges in designing this study which 
may have obscured possible associations. Owing to the various resolutions to which FSs have been 
previously mapped and the various criteria used to determine a site as fragile, classifying a genomic
region as a FS or a non-FS was not straight forward. Adding to this, the heterogeneity of cancer 
samples used, cell lines available for replication time data and cell types in which FS were detected,
it is possible that there are subtle associations still to be found. As with the outcome of chapter 3, 
chapter 4 has laid the ground for further studies in the not too distant future, where increased cohort 
sizes will provide better sample homogeneity which should allow for both greater sensitivity and 
specificity.
6.6  future directions
This thesis has demonstrated the importance of being able to analyse the DNMs directly as opposed 
to inferring patterns of DNM from comparative methods. There are currently ~43,000 DNMs 
available from pedigrees, so it is not possible to directly study the magnitude of variation in the 
germ-line below the 100kb scale. However this number is growing quickly and predicted to exceed 
100,000 by the end of 2016 (Wendy Wong, private communication). Thus it will soon be possible to
take the next logical step, and expand the work of chapter 5 to examine smaller windows, where I 
would expect the magnitude of mutation rate variation would increase. Increasing the resolution of 
this analysis in this way, combined with a more exhaustive interrogation of associated genomic 
features, should provide a deep insight into both the true determinants of mutation rate variation, 
and the processes driving patterns of divergence. One the most interesting insights from this thesis 
is the apparent disconnect between DNM density and divergence. This may suggest that many of 
the proposed determinants of mutation rate, such as replication time and chromatin architecture, 
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may have a greater influence on evolutionary processes than mutation. This is a particularly 
interesting hypothesis if we are to also consider patterns of somatic mutation. SNVs from cancer 
genomes are generally treated as somatic DNMs, in that they arose in the somatic tissue of the 
individual over a relatively short timescale - years as opposed to the millions of years of 
evolutionary time. Selection is also thought to be relaxed in somatic tissues (Yadav et al. 2016), so 
very little credence has been given to the possibility that patterns of somatic mutation may actually 
be dominated by evolutionary processes. However, if we consider, (i) evolutionary time in terms of 
the number cell divisions as opposed to absolute time, (ii) that clonal selection is highly prevalent in
cancers and, (iii) that cell proliferation in many cancers is rampant, then it is plausible that the 
patterns of somatic mutation may strongly reflect evolutionary pressures and therefore be more 
representative of divergence as opposed to germ-line DNM. This may also explain why a feature 
such as replication time exhibits considerable variation with somatic SNVs and divergence, but has 
a lesser impact on the rate of DNMs. The continual proliferation of SNV/DNM data coming from 
trio studies, cancer sequencing studies and initiatives such as the 100k genomes project over the 
next few years, should enable a shift away from the reliance on comparative methods to detect 
determinants of mutations, and result in a much deeper understanding of the forces of mutation and 
evolution in both the germ-line and the soma.
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Appendix 2.1
Appendix 2.1.  The complete dataset. Given are the number of sites with x DNMs, including those 
sites with no DNMs, but which when mutated would give a nonsense mutation.
Number of sites with x DNMs
Gene 0 1 2 3 4 5 6 7 8 9 10 11 12 13 52 54 61 85
RB1 CTS 11 97 0 0 0 0 0 1 1 2 1 2 1 1 1 1
CTV 9 5 6 2 0 1
NTS 44 15 33 8 2 1
NTV 327 32 301 20 6
NF1 CTS 18 52 1 3 5 6 1 0 0 1 0 0 1
CTV 12 4 10 0 2
NTS 187 24 166 18 3
NTV 851 20 831 20
MECP2 CTS 5 252 1 0 0 0 0 0 0 0 0 0 0 0 0 0 1 1 1 1
CTV 7 0 7
NTS 16 6 12 2 2
NTV 152 12 145 6 0 0 0 0 1
CTS 4 252 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 1 1 1
CTV 3 0 3
NTS 5 2 4 0 1
NTV 38 10 33 4 0 0 0 0 1
Mutational 
category
Number 
of sites
Number of 
DNMs
MECP2 - restricted
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Appendix 2.2
Appendix 2.2. The number of sites hit by a CpG transition nonsense DNM in RB1 in the three 
datasets, along with the probability from a test of heterogeneity.
Hits Houdayer Lohmann Onadim
0 0 0 2
1 1 1 4
2 2 2 2
3 2 4 1
4 4 1 0
5 2 2 1
6 0 0 1
7 0 1 0
Probability 0.85 0.81 0.086
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Appendix 2.3
Appendix 2.3. he number of DNMs at each site in RB1 at which a CpG transition causes a 
nonsense mutation in the three datasets. The three datasets do not show a significant difference in 
the pattern of mutation as assessed by a chi-square test, generating the null distribution by 
randomization.
Site Houdayer Lohmann Onadim
751 4 3 0
763 1 3 1
958 5 4 0
1072 4 3 6
1333 4 7 1
1363 3 5 3
1399 5 2 2
1654 3 2 2
1666 2 1 5
1735 2 3 1
2359 4 5 1
Total DNMs 37 38 22
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Appendix 2.4
Appendix 2.4. Log likelihood values for various models. The analysis is performed on the 
restricted MECP2 data. N is the number of parameters in each model. The figures in 
bold indicate the model favored by likelihood ratio tests - model 2 provides a significantly better fit 
to the data than model 1, whereas model 3 does not, and model 4 does not provide a significantly 
better fit than model 2.
Model no. Model description N Log liklihood
1 12 -101.39
2 15 -86.91
3 14 -98.89
4 22 -83.56
Gamma distribution shared across genes and mutational 
categories
Separate gamma distribution for each mutational 
category shared across genes
Separate gamma distribution for each gene shared across 
mutational categories
Separate gamma distribution for each gene and mutational 
category combination
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Appendix 3.1
Appendix 3.1. Genomic positions and seqeuncing centre origin of the excess liver cancers used for 
privacy calculations. NCC = National Cancer Centre Japan, RIKEN = RIKEN institute Japan.
GenomicPosition RIKEN NCC sum
X:56209339 6 0 6
10:96652829 6 0 6
10:96652827 6 0 6
X:56209340 5 0 5
5:85091859 5 0 5
5:1295228 0 5 5
9:121267366 4 0 4
8:119547627 4 0 4
19:22314552 1 2 3
14:95832895 1 2 3
9:16932821 2 1 3
7:27901228 2 1 3
4:162437670 2 1 3
3:164903710 2 1 3
Y:4796240 3 0 3
X:84996701 3 0 3
7:11432162 3 0 3
7:11432157 3 0 3
3:174306603 3 0 3
2:49173787 3 0 3
2:139556678 3 0 3
19:8673262 3 0 3
1:190881448 3 0 3
X:79125571 0 3 3
6:78532352 0 3 3
5:97912191 0 3 3
4:190837614 0 3 3
19:44959650 0 3 3
15:73206445 0 3 3
14:74659965 0 3 3
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Appendix 4.1
Appendix 4.1. The fit of separate quadratic terms for each aCFS tissue type and study (solid 
lineand crosses) and non-FS (dashed line and circles) windows.
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Appendix 5.1
Appendix 5.1. Graphs showing DNM density as a product of replication time. each point represents
one 1Mb window, values for both axes were normalised by dividing the score for each window by 
the mean for all windows, A, CpG transitions, B, strong (C/G) to weak (T/A) and weak to weak 
mutations, C, weak to strong and strong to strong mutations.
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Appendix 5.2
Appendix 5.2. Graphs showing mean alignment lengths versus divergence for the PW alignments 
(top panel) and the MZ alignments (bottom panel). Spearman's correlation coefficient was used to 
obtain r.
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Appendix 7. The variable association of replication time with SNV density.
The following observations arose tangentally to Chapter 4 whilst investigating the relationship of 
replication time with fragile sites and SNV density. I felt that this work was important but did not fit
within the framework of this thesis nor was it substantial enough to stand alone as a chapter. 
Therefore I have decided to include it in the appendix as a short aside highlighting the variability of 
the association of replication time with SNV density in cancers.
The effect of replication time on mutation has been widely documented in both germ-line and 
somatic tissues and it has become widely accepted that later replicating DNA harbours an 
increased rate of point mutations (Stamatoyannopoulos et al., 2009; Chen et al., 2010; Koren 
et al., 2012). We refer to this as phenomenon as replication time dependent mutagenesis 
(RTAM). In somatic tissues it has been claimed that functional mismatch repair (MMR) 
underlies RTAM  (Supek & Lehner, 2015).  We show that, in a cohort of 160 samples that 
there is extensive variation in RTAM that is not linked to MMR deficiency and demonstrate 
that other determinants of RTAM are at least as important in cancer samples.
From the 507 publicly available whole genome sequenced cancer samples published by Alexandrov
et al. (Alexandrov et al., 2013), we selected 160 samples which contained over 3,000 SNVs each. 
These were comprised of 24 lung, 78 liver, 10 pancreatic and 48 breast cancers, none of which are 
commonly associated with MMR deficiency (Cunningham et al., 1998; Miyakura et al., 2001; 
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Chiappini et al., 2004; Gargiulo et al., 2009). We examined the distribution of SNVs in these 
sample as a function of replication time. Using the mean replication time of 5 cell lines (Hansen et 
al., 2010) (see methods) we divided the genome into quintiles. We quantified the level of RTAM in 
terms of a quintile enrichment score (QES), which is the number of SNVs in the latest replicating 
quintile divided by the number of SNVs in earliest replicating quintile; we favoured this method as 
opposed to a linear regression as there is evidence that there is a non-linear relationship in the 
extremely late replicating regions. QES differs significantly amongst cancer genomes ranging 6-
fold from 0.81 to 5.42 (Chi-square test p < 10-16) (Fig. 1, also see specific examples in Fig. 2a-f). 
Unfortunately, not being in possession of the original 160 samples, we could not directly test them 
for MMR deficiency by looking for micro satellite instability (MSI) in the usual manner (Umar et 
al., 2004). However, mutational signatures 6, 15, 20 and 26 from Alexandrov et al. (Alexandrov et 
al., 2013) are indicative of MMR. To date, signature 15 has never been reported in the 4 cancer 
types covered in these 160 samples. Signatures 20 and 26 have been found in breast cancers, but 
only at frequencies <3%, and signature 6 has been found across all cancers, but again only at low 
frequencies (<3%) (http://cancer.sanger.ac.uk/cosmic/signatures). From the 160 samples, Only one 
sample, HX13T, showed sufficient levels of signature 6 to be classified as MMR deficient. HX13T 
does exhibit an attenuated QES of 1.27 (Fig. 2c). A further 10 samples (Supplemental data) exhibit 
very low levels of signature 6 that could be due to low-level sub-clonal MSI or limitations of the 
methodology used to detect the signatures, however the remaining 149 samples contain no traces of 
any of the MMR signatures (Alexandrov, L., personal communication). Furthermore, none of these 
samples contained exonic mutations in MLH1, MSH2, MSH6 and PMS2, mutations in which genes 
cause MSI in >90% of Lynch syndrome cases (Fishel et al., 1993; Bronner et al., 1994). 
160
Figure 1. 160 samples ranked by their quintile enrichment scores and coloured by cancer type. 
Vertical lines represent 1 standard deviation
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We identified 4 samples (LUAD-S01345, PD4120a, PD4199a and PD6722a) from the 149 MMR 
proficient samples that demonstrated a complete lack of RTAM (Fig. 2a-b) (i.e. QES ≤ 1). The low 
QES found in these 4 samples is in stark contrast to a QES of ~2-6 that was found in previous 
studies in humans (Koren et al., 2012) and yeast (Lang & Murray, 2011) and the median QES of 
2.78 found when considering all 160 samples (Fig. 2e). It was conspicuous that 3 of the 4 low-QES 
samples were breast cancers. Ranking each of the 160 samples by their QES showed that breast 
cancers dominated the low scores (Fig. 1 and Supplemental data) and confirmed that there are 
significant differences between cancer types (Kruskel-Wallis test p < 10-16) (Fig 2f). Strikingly the 
median QES for breast cancers is 1.56, only slightly greater than the median QES amongst the 
MMR-deficient cancers as studied by Supek and Lehner (median QES scores for MMR deficient 
colorectal cancer = 1.47, uterine cancer = 1.30, stomach cancer = 1.43 and pooled tissues = 1.42, 
calculated from original data in [1] provided by Supek & Lehner). To exclude cell line specificity of
the replication timing data being the cause of the low median QES for breast cancers, we also used 
replication time data from the breast cancer derived MCF-7 cell line (Hansen et al., 2010). In this 
case similar results were obtained (data not shown). Additionally it has been shown that regions of 
the genome exhibiting extremely late/early replication time are remarkably stable [REF]. It is 
therefore evident that not only is there very large variation in the degree of RTAM that is not 
associated with MMR status, but that cancers can have no RTAM even when they are MMR 
proficient.
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Figure 2.  Variation of replication time associated mutagenesis (RTAM) across mismatch repair 
(MMR) proficient cancer samples. a-c, Single nucleotide variant (SNV) counts across replication 
time quintiles for 3 low-QES samples, LUAD-S01345, PD4120a, PD4199a, which exhibit a lack of 
RTAM. d, Same as a-c but for HX13T, the only confirmed MSI sample e, Same as a-d but summed 
across all 160 samples illustrating the median QES = 2.78. f, Boxplot of median QES for each 
cancer type, box limits indicate inter quartile ranges (IQR), whiskers denote the limits of extreme 
values or 1.5xIQR, whichever is lesser, open circles denote outlying samples.
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The reason why breast cancers show low RTAM is unclear. However it is interesting to note that the
4 low-QES samples all show high levels of signatures 2 and 13, indicative of of APOBEC induced 
hyper-mutation (Alexandrov, L., personal communication). As estrogen has been shown to induce 
expression of the AID/APOBEC family of deaminases (Pauklin et al., 2009), one hypothesis could 
be that hormonally driven cancers are more likely to over-express APOBEC proteins, and the 
resulting hyper-mutation may occur independently of replication time. Since the initial discovery of 
this pattern, it has been shown that APBOEC over-expression is a likely candidate for the the lack 
of RTAM  (Morganella et al., 2016).
We conclude that although MMR may be a determinant of RTAM in cancers that are commonly 
associated with MMR, such as colorectal, stomach or uterine cancers, it is rarely likely to be the 
major determinant of RTAM in other cancers. Not only have our findings shown the existence of 
MMR proficient cancer samples with a complete lack of RTAM, they have also shown that the 
extent of RTAM varies >6 fold across diverse cancer types, the vast majority of which are not MMR
deficient and that >10% of cancer samples exhibit attenuated RTAM to a level lower than the MMR
deficient median. We also show that RTAM is associated with cancer type, with relatively low QES 
in breast cancers and the highest QES in lung cancers (Fig 1, Fig 2f). Therefore upon this evidence, 
we suggest that other determinants, including, but not limited to, cancer type and APOBEC over-
expression, likely contribute to RTAM to a greater degree than does variable MMR.
Methods
Replication timing data and dividing the genome into 100 kb windows. 
We downloaded Encode Repli-seq wavelet smoothed signal data (Hansen et al., 2010) aligned to the
reference genome (HG19/GRCh37) for the GM12878, HeLa, HUVEC, K562, HepG2 and MCF-7 
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cell lines from the UCSC ftp site ftp://hgdownload.cse.ucsc.edu/goldenPath/hg19/database/. We 
computed the mean replication time for chromosomes 1-22 and X in non-overlapping 100 kb 
windows across the GM12878, HeLa, HUVEC, K562, HepG2 cell lines. We used the Repli-Seq 
start coordinates for each chromosome (bp 24500) to denote the beginning of the first window. 
Chromosome Y was not included as no replication time data was available. Any windows 
containing unknown bases (denoted as N in the reference genome) were excluded from the analysis.
This resulted in 28,080 100 kb windows remaining. The windows were ranked by their mean 
replication times and divided into quintiles each containing 5616 100 kb windows. We also used 
replication time data from the MCF-7 cell line to control for tissue specific effects.
Single nucleotide variants.
The 160 Sample IDs were extracted from Supplementary Table 1 in (Supek & Lehner, 2015). Single
nucleotide variants (SNVs) for breast, liver, lung and pancreatic cancers from (Alexandrov et al., 
2013) were downloaded from 
ftp://ftp.sanger.ac.uk/pub/cancer/AlexandrovEtAl/mutational_catalogs/genomes/ and filtered to 
retain only the SNVs from the 160 samples resulting in a total of 2,838,468 SNVs. These SNVs 
were assigned to their relevant 100 kb windows and total SNV and total counts per window was 
calculated. Each window was assigned to its relevant replication time quintile and SNVs summed 
for each quintile. 
Detection of MMR deficiency in samples.
MMR status of 160 samples was confirmed via personal communication from Ludmil Alexandrov 
after determination of levels of 4 known MMR signatures 6,16,20 and 26 from (Alexandrov et al., 
2013).
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Statistical analysis.
Quintile enrichment scores were calculated by dividing the sum of SNVs in the latest replicating 
quintile (Q1) by sum of SNVs in the earliest replicating quintile (Q1). R version 3.1.3 was used for 
all statistics (stats package); Chi Squared test was used to test for significant differences in QES 
between the 160 samples, Kruskel-Wallis test was used to test for significant differences in the 
median QES between cancer types and variances and standard deviations were calculated for each 
QES shown in figure 2. QES scores for the MSI colorectal, stomach, uterine and pooled intergenic 
regions were manually calculated from the original data used to produce the graphs 2e-g in (Supek 
& Lehner, 2015) by dividing the median relative SNV frequency in the latest replicating quintile by 
the median SNV frequency in the earliest replicating quintile.
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